Doc #119 — Local Pharmaceutical Production: Honest Assessment

---

ECONOMIC JUSTIFICATION

7.1 Labour requirements

Pharmaceutical Production Development Group: Approximately 20–50 full-time-equivalent skilled personnel in Phase 1–3, growing to 100–200 in Phase 4–5. This includes chemists, pharmacists, chemical engineers, agricultural workers (opium poppy cultivation), quality control staff, and support personnel.

For context: NZ’s population of approximately 5.2 million has roughly 2.5 million working-age people. Dedicating 50–200 workers to pharmaceutical production is a negligible fraction of the workforce. The economic justification does not need to be elaborate: pharmaceutical production directly prevents thousands of deaths and enables surgical and medical care that would otherwise be impossible. The return on investment, measured in lives, is enormous.

7.2 Comparison with alternatives

Alternative 1: Do nothing — rely solely on rationing and SLEP extension.

• Physical supply of most drug categories lasts roughly 5–14 months under aggressive rationing (Doc #116, Section 9.3). SLEP ensures pills remain chemically effective during this period but does not create more supply.
• After stock exhaustion, NZ has no analgesics, no antibiotics, no anaesthetics
• Surgery becomes impractical; bacterial infections become frequently fatal
• This is not a viable long-term strategy

Alternative 2: Wait for trade.

• If Australia or another trading partner develops pharmaceutical production, NZ could import
• But this depends on another country solving the same industrial chemistry problems, which is uncertain
• NZ cannot plan on the assumption that someone else will solve this

Alternative 3: Invest in local production (this document).

• Requires modest labour investment (50–200 workers)
• Provides analgesics, anaesthetics, antibiotics, and antiseptics over a 3–10 year development timeline
• Does not solve the entire pharmaceutical gap but addresses the most critical needs
• The only option within NZ’s own control

7.3 Breakeven

The concept of “breakeven” does not apply straightforwardly to pharmaceutical production — the output is not measured in economic terms but in medical capability and lives saved. However: the first litre of sterile IV saline, the first dose of locally produced morphine, the first batch of crude penicillin — each of these represents a capability that NZ permanently lacks without the production programme. There is no alternative source. The programme begins “paying back” from the first dose administered.

---

1. NZ’S STARTING POSITION

1.1 What NZ has

Chemical knowledge. NZ has university chemistry departments (University of Auckland, University of Otago, Victoria University of Wellington, University of Canterbury, Massey University) with staff who understand organic synthesis, analytical chemistry, and pharmaceutical science. The University of Otago School of Pharmacy and University of Auckland School of Pharmacy have specific pharmaceutical manufacturing expertise.¹ This knowledge is essential and perishable — capturing it from aging academics before they retire or die is a Phase 1 priority.

Laboratory equipment. University and hospital laboratories have glassware, fume hoods, analytical instruments (HPLC, mass spectrometry, UV-Vis spectrophotometry, dissolution testing apparatus), autoclaves, and basic chemical processing equipment.² This equipment is finite and irreplaceable when it breaks, but it provides a starting platform for small-scale production and quality control.

Some raw materials. NZ has:

• Ethanol production capability (fermentation from grain, sugar, or fruit — well-established)³
• Sulfur (from geothermal sources — Rotorua, Taupo region)⁴
• Limestone (abundant — multiple quarries nationwide)⁵
• Salt (from seawater evaporation or the salt works at Lake Grassmere, Marlborough)⁶
• Seaweed (kelp species for iodine extraction — abundant around NZ coastline)⁷
• Tallow (from NZ’s substantial livestock industry)⁸
• Charcoal (from NZ’s forestry resource — Doc #100)
• Zinc ore (limited — small deposits exist but NZ is not a significant zinc producer)⁹
• Sheep intestine (for catgut sutures — NZ has approximately 26 million sheep)¹⁰
• Arable land for medicinal plant cultivation (opium poppy, willow, various medicinals)

Douglas Pharmaceuticals (Auckland). NZ’s largest domestic pharmaceutical manufacturer has tableting equipment, encapsulation machines, coating equipment, and packaging lines.¹¹ This infrastructure can produce finished dose forms from APIs — but the APIs must come from somewhere. The factory is valuable for the final step of production, not for the chemical synthesis itself.

1.2 What NZ does not have

Petrochemical feedstocks. The majority of modern pharmaceutical synthesis begins with petrochemical precursors — benzene, toluene, phenol, aniline, and their derivatives. NZ has no oil refinery operating at capacity (Marsden Point refinery at Whangarei ceased refining operations in 2022 and converted to an import terminal).¹² Without petrochemicals, most organic synthesis pathways taught in chemistry textbooks are not available. Alternative feedstocks exist (coal tar, wood tar, fermentation products) but yield different precursors at much lower volumes and purities.

Industrial organic chemistry infrastructure. NZ has no large-scale chemical synthesis plants for organic intermediates. No capacity for producing phenol, aniline, salicylic acid, p-aminobenzoic acid, sulfonamide precursors, or any of the thousands of intermediates that modern pharmaceutical manufacturing requires.¹³

Sulfuric acid at scale. Sulfuric acid is the most important industrial chemical — required for dozens of pharmaceutical and chemical processes. NZ does not currently produce sulfuric acid domestically, though the raw material (geothermal sulfur) exists. Establishing sulfuric acid production is a prerequisite for much of what this document describes (see dependency on Doc #113).¹⁴

Hydrochloric acid at scale. Required for many pharmaceutical processes. Can be produced from salt and sulfuric acid (Leblanc process) — but requires sulfuric acid first.¹⁵

Pharmaceutical-grade glass. Ampoules, vials, and laboratory glassware require borosilicate glass. NZ has some glass manufacturing (O-I Glass, Auckland), but borosilicate glass production requires specific raw materials (borax) that NZ does not produce and would need to import or substitute.¹⁶

Analytical instruments for quality control. The existing laboratory instruments are finite. When an HPLC column degrades, when a UV lamp burns out, when a mass spectrometer’s vacuum pump fails — these cannot be replaced from NZ manufacturing. Quality control capability degrades over time as instruments fail. This is one of the most serious long-term constraints, because producing pharmaceuticals without quality control is worse than not producing them at all.

Sterile manufacturing capability at scale. Making sterile injectable products (IV fluids, injectable antibiotics, insulin) requires clean rooms, HEPA filtration, sterile filling equipment, and validated sterilisation processes. NZ has some of this in hospital pharmacy compounding suites and at Douglas Pharmaceuticals, but scaling up sterile manufacturing is a major engineering challenge.¹⁷

1.3 The dependency chain problem

Every pharmaceutical production process described in this document depends on precursor chemicals, equipment, and infrastructure that themselves depend on other precursor industries. This is the dependency chain problem described in the style guide, and it is particularly severe for pharmaceuticals.

Example: Aspirin production.

The textbook synthesis of aspirin is straightforward: salicylic acid + acetic anhydride = acetylsalicylic acid (aspirin). But:

1. Salicylic acid is produced by the Kolbe-Schmitt reaction: sodium phenoxide + carbon dioxide under pressure and heat = sodium salicylate, then acidified to salicylic acid.
2. Sodium phenoxide requires phenol + sodium hydroxide (caustic soda).
3. Phenol — here is the problem. Industrial phenol is produced from cumene (a petrochemical) via the cumene process, or historically from coal tar distillation. NZ has neither a cumene process plant nor coal tar distillation capability. Phenol could potentially be extracted from coal tar if NZ develops coal tar production (from coal pyrolysis/coking), but this is itself a significant industrial development requiring coal mining, coke ovens, and fractional distillation of tar.¹⁸
4. Acetic anhydride is produced industrially from acetic acid (which can be made by fermentation — vinegar — or from methanol and carbon monoxide). Acetic anhydride production from acetic acid requires a catalyst (typically a phosphorus compound) and is not trivial chemistry at scale.¹⁹
5. Carbon dioxide — available (fermentation byproduct, limestone calcination).
6. Sodium hydroxide (caustic soda) — can be produced by electrolysis of brine (chloralkali process), which requires the electrical grid and salt. NZ can do this (see Doc #112).²⁰

So aspirin production requires: coal tar distillation or an alternative phenol source, caustic soda production, CO2 supply, acetic anhydride production, and the Kolbe-Schmitt reaction itself (which requires pressure vessels rated for 100+ atmospheres and temperatures of 125°C). Each link in this chain must be established before aspirin production begins. This is why the timeline is years, not months.

Every drug in this document has a similar dependency chain. The chains overlap — sulfuric acid, caustic soda, ethanol, and basic laboratory glassware appear repeatedly — which means that establishing a few key precursor industries unlocks multiple pharmaceutical products simultaneously. But those precursor industries must come first.

---

2. TIER 1: ACHIEVABLE WITHIN 1–3 YEARS

These products require minimal industrial chemistry and can be produced using knowledge, equipment, and materials that NZ already possesses or can develop quickly.

2.1 Oral rehydration salts (ORS)

What it is: A precise mixture of sodium chloride, potassium chloride, sodium citrate (or sodium bicarbonate), and glucose dissolved in clean water. The WHO-recommended formula is one of the most important medical interventions ever developed — it prevents death from dehydration due to diarrhoeal disease, which will become more common as sanitation degrades in some settings.²¹

Production difficulty: Low. The chemistry is mixing measured quantities of salts and sugar, but accurate measurement matters: incorrect concentrations — particularly excess sodium — can cause hypernatraemia, and insufficient salt produces an ineffective solution.²² A calibrated scale accurate to ±1 gram and a one-litre measure are the minimum equipment. Hospital and community pharmacies can produce ORS reliably; improvised production in a general kitchen setting requires training to achieve the necessary precision.

NZ materials: All available. Salt (Lake Grassmere or seawater evaporation), potassium chloride (fertiliser-grade KCl is available in NZ’s agricultural supply chain; pharmaceutical-grade requires purification), sodium bicarbonate (baking soda — in NZ retail and wholesale supply), glucose or sucrose (from NZ sugar supplies or honey).

Quality control: The critical quality issue is accurate measurement — incorrect concentrations can be harmful (hypernatraemia from too much salt, or ineffective rehydration from too little).²³ Pharmacists and trained health workers can produce ORS accurately using calibrated scales and standard volumetric measures. Pre-measured sachets should be produced and distributed widely to avoid production errors at the point of use.

Feasibility: [A]. NZ can produce this immediately with existing capability. Should be one of the first items produced at scale.

Medical value: High. Diarrhoeal disease mortality increases substantially without modern sanitation infrastructure. ORS is the primary treatment.

2.2 Ethanol (antiseptic, solvent, and pharmaceutical excipient)

What it is: Ethyl alcohol, produced by fermentation and distillation. Used as a wound antiseptic (at 60–80% concentration), a solvent for tinctures and extracts, and a precursor for ether production.

Production difficulty: Low. Ethanol production by fermentation of sugars or starches followed by distillation is one of the oldest chemical processes known. NZ already has whisky distilleries, craft spirit producers, and industrial ethanol capability.²⁴

NZ materials: Any fermentable carbohydrate source — grain, potatoes, sugar beet, fruit, honey, whey (from NZ’s dairy industry). Whey is particularly interesting: NZ’s dairy processing generates large volumes of whey, which contains lactose that can be fermented to ethanol.²⁵

Production process:

1. Fermentation: Yeast (Saccharomyces cerevisiae) converts sugars to ethanol and CO2. Standard brewing/distilling technology. Yields ~8–15% ethanol in the fermented wash.
2. Distillation: Copper pot stills or column stills concentrate ethanol to 90–95%. NZ has distillation equipment at existing spirit producers and can fabricate simple stills from copper sheet (available from NZ’s copper stock, though copper is imported and finite).
3. For pharmaceutical use: redistillation to higher purity, potentially with drying agents (calcium oxide / quicklime from NZ limestone) to achieve >95% ethanol.

Quality control: Relatively straightforward. Specific gravity measurement (hydrometer — simple instrument, can be locally made from glass) determines ethanol concentration. The main quality risk is methanol contamination — which occurs when fermentation feedstock contains pectin (fruit-based fermentations). Distillation technique (discarding the foreshots) manages this risk. This is well-understood by distillers.²⁶

Feasibility: [A]. NZ can scale up ethanol production within months using existing distilleries and fermentation knowledge.

Medical value: High. Ethanol is the foundation for wound antisepsis when modern antiseptics (chlorhexidine, povidone-iodine) are depleted. Also the precursor for ether (Section 2.4) and a solvent for producing tinctures of medicinal plants.

2.3 Basic IV saline (0.9% sodium chloride)

What it is: Sterile water containing 0.9% sodium chloride (normal saline). Used for intravenous fluid replacement, wound irrigation, and as a vehicle for injectable medications.

Production difficulty: Moderate. The chemistry is trivial — dissolving salt in water. The challenge is sterility. Injectable fluids must be sterile and pyrogen-free (free from bacterial endotoxins that cause fever and potentially fatal reactions). Achieving this requires distilled or deionised water, pharmaceutical-grade salt, sterile containers, and validated sterilisation (autoclaving).²⁷

NZ materials: Salt (Lake Grassmere or evaporated seawater, purified to pharmaceutical grade), distilled water (from simple distillation apparatus), glass bottles or NZ-produced containers (plastic bags require specialised film that NZ may not be able to produce).

Production process:

1. Purify salt to pharmaceutical grade: dissolve, filter, recrystallise, dry.
2. Produce pyrogen-free water by distillation (not just filtration — distillation removes pyrogens).
3. Dissolve salt to 0.9% concentration (9g per litre).
4. Fill into clean glass bottles.
5. Autoclave at 121°C for 15 minutes.
6. Test a sample from each batch: clarity, pH, sterility testing (incubation to check for microbial growth), pyrogen testing if capable.

Quality control: This is where the difficulty lies. Hospital pharmacies currently compound small volumes of sterile fluids using validated equipment and processes. Scaling up to supply a national healthcare system requires more equipment, more trained staff, and rigorous process validation. Contaminated IV fluids can kill patients — there is no margin for error.²⁸

Feasibility: [B]. NZ has the knowledge and some equipment. Scaling up is the challenge.

Medical value: Very high. IV fluids are essential for surgical patients, burn patients, patients with severe dehydration, and as vehicles for injectable medications. Without IV saline, surgery becomes much more dangerous and many treatable conditions become fatal.

2.4 Ether (diethyl ether — general anaesthetic)

What it is: Diethyl ether, the first widely used general anaesthetic (from the 1840s). Produced by dehydration of ethanol with sulfuric acid. Still effective and usable, though largely replaced by modern anaesthetics (sevoflurane, propofol) in contemporary practice.²⁹

Production difficulty: Moderate. The chemistry is well-established: heat ethanol with concentrated sulfuric acid at 140°C, collect ether vapour by distillation. The process is hazardous — ether is extremely flammable, heavier-than-air ether vapour accumulates at floor level, and ether can form explosive peroxides on storage.³⁰

NZ materials: Ethanol (Section 2.2) and sulfuric acid (Doc #113 — this is a dependency; sulfuric acid production must be established first).

Production process:

1. Slowly add ethanol to concentrated sulfuric acid at 140°C.
2. Ether vapour distils off and is condensed and collected.
3. Wash the condensate with water, then with dilute sodium hydroxide, then with water again to remove sulfuric acid and ethanol impurities.
4. Dry over calcium chloride or sodium sulfate.
5. Store in dark, airtight containers with a small amount of copper wire (inhibits peroxide formation).

Quality control: Critical. Impure ether is dangerous to patients. Testing for:

• Peroxide content (starch-iodide test — simple but essential; peroxide-containing ether can explode)
• Residual acidity (pH testing)
• Water content
• Residual sulfuric acid or ethanol

A basic chemistry laboratory can perform these tests. The requirement is disciplined adherence to testing protocols, not sophisticated equipment.

Substitution performance gap: Ether anaesthesia is functional but significantly inferior to modern balanced anaesthesia (propofol induction, sevoflurane maintenance, neuromuscular blockade). Key differences affecting patient outcomes:

• Induction time: 3–10 minutes with ether vs. under 1 minute with propofol. Prolonged induction is distressing and increases risk in unstable patients.
• Airway irritation: ether stimulates mucus secretion and bronchospasm; higher rate of aspiration and respiratory complications than modern agents.
• Post-operative nausea and vomiting: very common with ether (~50–75% of patients) vs. ~10–20% with modern agents; in a setting where IV antiemetics are limited, this is a significant complication.
• Fire risk: ether vapour is flammable at 1.9–36% concentration in air and heavier than air, accumulating at floor level. No electrocautery, no diathermy, no open flames. Procedures requiring these are not safely performable under ether.
• Muscle relaxation: ether provides some muscle relaxation at deep planes; modern neuromuscular blocking agents are unavailable. Deep ether planes needed for relaxation carry risk of overdose.
• Mortality: modern anaesthetic mortality (attributable to anaesthesia) is approximately 1:100,000. Historical ether mortality was approximately 1:5,000–15,000.³¹ This gap is substantial and must be communicated to patients and surgical teams.

Surgeons and anaesthetists trained in modern practice will need retraining in ether anaesthesia techniques, which were last taught routinely in NZ medical schools decades ago.³²

Feasibility: [B]. Depends on sulfuric acid production (Doc #113). Once sulfuric acid is available, ether production is achievable.

Medical value: High. General anaesthesia is essential for surgery. When modern anaesthetics (propofol, sevoflurane) are depleted, ether and chloroform (Section 3.3) are the fallback. Without general anaesthesia, surgery regresses to pre-1846 conditions — conscious, restrained patients.

2.5 Iodine tincture (antiseptic)

What it is: Iodine dissolved in ethanol, used as a topical antiseptic. One of the oldest and most effective antiseptics.³³

Production difficulty: Moderate. Extracting iodine from seaweed is established chemistry — it was the primary source of iodine before Chilean mineral deposits were exploited in the 19th century. NZ’s coastline provides abundant kelp.³⁴

NZ materials: Kelp/seaweed (abundant — Macrocystis pyrifera, Ecklonia radiata, and other species around NZ coast), ethanol (Section 2.2).

Production process:

1. Harvest seaweed. Dry it. Burn to ash (kelp ash).
2. Leach the ash with water to dissolve soluble salts including iodide salts.
3. Add sulfuric acid and an oxidising agent (manganese dioxide from NZ’s mineral deposits, or chlorine from the chloralkali process) to convert iodide to elemental iodine.
4. Collect iodine crystals by distillation or filtration.
5. Dissolve in ethanol to make tincture of iodine (typically 2–7% iodine in alcohol).

Yield: Low. Seaweed contains approximately 0.03–0.5% iodine by dry weight, depending on species and conditions.³⁵ Producing useful quantities of iodine requires processing large volumes of seaweed. This is labour-intensive but feasible as a cottage industry in coastal communities.

Quality control: Relatively simple. Iodine concentration can be estimated by colour intensity or measured by titration (sodium thiosulfate titration — basic analytical chemistry). The product does not need to be sterile — it is an antiseptic applied to skin.

Feasibility: [A/B]. Achievable with modest chemistry capability. Labour-intensive but low-tech.

Substitution performance gap: Iodine tincture in ethanol is broadly effective against bacteria, viruses, fungi, and spores, and was the standard surgical antiseptic before povidone-iodine and chlorhexidine replaced it. Compared to modern alternatives: (a) tincture of iodine causes more skin irritation and is toxic to mucous membranes — it cannot be used for urethral, vaginal, or wound cavity irrigation the way povidone-iodine solution can; (b) it stains tissue and linen significantly; (c) allergy to iodine (approximately 1–3% of population) is a contraindication.³⁶ Chlorhexidine, which NZ cannot produce locally, has superior residual activity on skin. Iodine tincture is an adequate substitute for skin preparation before injections and minor surgery, but practitioners must be aware of the contraindications that did not apply to the products it replaces.

Medical value: High. Wound antisepsis prevents infection that, in the absence of antibiotics, would frequently be fatal.

2.6 Zinc oxide paste

What it is: Zinc oxide suspended in a base (petroleum jelly, lanolin, or plant oil). Used for wound protection, nappy rash, and as a component of calamine lotion. Zinc oxide also has mild antimicrobial properties.³⁷

Production difficulty: Low to moderate, depending on zinc source. If metallic zinc is available (from depleting stocks or small NZ deposits), zinc oxide is produced by heating zinc in air. If zinc must be smelted from ore, the difficulty increases substantially.

NZ materials: NZ has limited zinc deposits. Zinc is present in some polymetallic ore bodies, and small quantities could potentially be recovered from electronic waste (circuit boards, galvanised steel) during the pre-war equipment salvage period. Lanolin is abundant — NZ produces approximately 1,500–2,000 tonnes of lanolin per year from wool scouring.³⁸

Feasibility: [B] (from stockpiles or e-waste) / [C] (from ore). If metallic zinc can be recovered from pre-event stocks, galvanised steel scrap, or electronic waste, zinc oxide production is achievable within years 1–3. If NZ must smelt zinc from ore, the dependency chain extends substantially: zinc ore must be mined (limited NZ deposits in Coromandel/Northland region), concentrated by flotation, and smelted at approximately 900°C under reducing conditions — requiring engineering infrastructure and expertise not yet available in Phase 1–2.³⁹

Medical value: Moderate. Useful for wound care and dermatological conditions but not life-saving.

2.7 Activated charcoal

What it is: Charcoal that has been treated to increase its surface area and adsorptive capacity. Used for poisoning treatment (oral administration to adsorb toxins in the GI tract) and water purification.⁴⁰

Production difficulty: Low to moderate. Charcoal is produced from wood (Doc #100). Activation can be achieved by:

• Chemical activation: treating charcoal with phosphoric acid or zinc chloride before pyrolysis. Requires the relevant acid (phosphoric acid is not currently produced in NZ) or zinc chloride (limited NZ zinc supply).
• Physical activation: heating charcoal to 800–1000°C in the presence of steam or CO2 for 30–120 minutes. Requires a furnace capable of sustained operation at 800–1000°C with a refractory lining, a source of steam or CO2, and temperature control. This is more demanding than charcoal production alone (which peaks at 400–600°C in the absence of air), but achievable using kiln technology available in NZ’s forestry and ceramics sectors.

The physical activation method avoids chemical dependencies and is preferred given NZ’s constraints, though it requires a higher-temperature kiln than charcoal production alone.⁴¹

NZ materials: Wood (abundant — NZ forestry), heat source, steam.

Quality control: Adsorptive capacity can be tested by measuring how much methylene blue or iodine the charcoal adsorbs from solution — simple laboratory tests.

Feasibility: [A]. NZ can produce this with existing capability.

Medical value: Moderate. Important for managing poisoning (accidental or intentional). Also valuable for water purification.

2.8 Soap (antiseptic barrier)

What it is: The product of saponification — reacting fat or oil with an alkali (sodium hydroxide for hard soap, potassium hydroxide for liquid soap). Soap is the foundation of infection control. Handwashing with soap is more effective at preventing disease transmission than most antiseptics.⁴²

Production difficulty: Low. Soap-making is genuinely simple chemistry that has been practiced for millennia. NZ has abundant tallow (from livestock processing) and can produce sodium hydroxide (caustic soda) from the chloralkali process (Doc #112).

Feasibility: [A]. NZ can produce soap immediately and at scale. This should be treated as an essential public health product, not a pharmaceutical per se.

Medical value: Very high. Soap and handwashing prevent more infections than antibiotics treat.

2.9 Lime water and milk of lime

What it is: Calcium hydroxide in water. Used as an antacid, for water treatment, and as a component of various traditional wound treatments. Also important as a chemical reagent for other pharmaceutical processes.

Production difficulty: Low. The chemistry is well-established: heat limestone (calcium carbonate) at approximately 900°C in a lime kiln to produce quicklime (calcium oxide), then add water carefully (an exothermic reaction) to produce slaked lime (calcium hydroxide). Dissolve in water for lime water; suspend in water for milk of lime. NZ has operating lime kilns at multiple quarry sites (Oparure, Otorohanga, South Island operations), so the production infrastructure already exists at scale.⁴³ At small scale, a simple wood-fired kiln constructed of stone or brick can achieve the required temperature, though fuel consumption is significant (approximately 3–5 tonnes of wood fuel per tonne of quicklime produced).⁴⁴

NZ materials: Limestone is abundant throughout NZ. Major quarries at Oparure (Waikato), Otorohanga, and multiple South Island locations.⁴⁵

Feasibility: [A].

---

3. TIER 2: ACHIEVABLE WITHIN 3–10 YEARS

These products require developing chemical production capability that does not currently exist in NZ but can be built from available knowledge and materials. Each has specific precursor dependencies that must be resolved first.

3.1 Aspirin (acetylsalicylic acid)

What it is: The most widely used analgesic and anti-inflammatory in history. Also an antiplatelet agent (low-dose aspirin for cardiovascular prevention). A single molecule with enormous medical utility.⁴⁶

Why willow bark is not an adequate substitute: Willow bark contains salicin, which the body converts to salicylic acid. It is sometimes presented as a natural alternative to aspirin. The problem is dosing: salicin content in willow bark varies enormously by species, season, harvest time, and preparation method — approximately 1–12% by dry weight across Salix species.⁴⁷ This variability makes reliable dosing impossible. For mild headache, variability is tolerable; for managing post-surgical pain, fever in a critically ill patient, or antiplatelet therapy, it is not. Willow bark extract is a supplement, not a medicine. Aspirin synthesis is necessary because it produces a pure, consistent, measurable product.⁴⁸

Production process (Kolbe-Schmitt synthesis + acetylation):

1. Obtain phenol. This is the critical bottleneck. Options:

   • Coal tar distillation: If NZ develops coal coking (for steel production at Glenbrook or elsewhere — Doc #89), coal tar is a byproduct. Fractional distillation of coal tar yields a “carbolic acid” fraction that is crude phenol. Purification by further distillation and crystallisation.⁴⁹ This is the most likely NZ pathway but depends on coal coking infrastructure.
   • Biosynthesis: Some microorganisms produce phenol or phenolic compounds from glucose. This is an active area of research but not at production scale anywhere in the world as of 2025.⁵⁰ Not a realistic near-term option.
   • From existing stocks: Phenol is used as a disinfectant and in some industrial processes. NZ may hold limited stocks. These would be consumed quickly.

2. Produce sodium phenoxide. React phenol with sodium hydroxide (caustic soda, from chloralkali process — Doc #112). The reaction is well-established acid-base chemistry, but requires caustic soda production to be operational first (see Doc #112 dependency) and handling of phenol, which is acutely toxic — skin contact causes deep burns and systemic toxicity.

3. Kolbe-Schmitt reaction. Heat sodium phenoxide under high-pressure CO2 (approximately 100–150 atmospheres) at 125°C for several hours. This produces sodium salicylate.⁵¹ The challenge: this requires a pressure vessel rated for industrial pressures. NZ has engineering workshops (Doc #91) that could fabricate such a vessel, but design and certification for high-pressure chemical service is non-trivial.

4. Acidification. Add sulfuric acid (Doc #113) to sodium salicylate solution to precipitate salicylic acid. Filter, wash, and dry.

5. Acetylation. React salicylic acid with acetic anhydride (see dependency below) in the presence of a catalyst (phosphoric acid or sulfuric acid). This produces aspirin. Recrystallise from a suitable solvent for purification.⁵²

6. Tablet production. The purified aspirin is mixed with excipients (starch, compressed with tableting equipment — Douglas Pharmaceuticals has this).

Acetic anhydride dependency. Acetic anhydride is used in aspirin synthesis and is also a controlled chemical (it is a precursor for heroin manufacture). It can be produced from acetic acid (vinegar — NZ can produce this by fermentation) via ketene intermediate, but this requires specialised equipment. Alternative: direct acetylation using acetyl chloride, which itself requires acetic acid and phosphorus trichloride or thionyl chloride — all of which have their own dependency chains.⁵³

Quality control: Aspirin purity can be assessed by melting point determination (pure aspirin melts at 135°C), titration (acid-base or iodometric), and thin-layer chromatography (TLC — a relatively simple analytical technique that NZ laboratories can perform). HPLC is ideal but not essential for basic quality assurance.

Feasibility: [C]. The phenol dependency is the binding constraint. If NZ develops coal tar distillation (likely tied to steel industry development), aspirin becomes feasible. Without a phenol source, it is not. Timeline: probably 5–10 years at best, depending on broader industrial chemical development.

Medical value: Very high. Aspirin treats pain, fever, and inflammation. Low-dose aspirin prevents heart attacks and strokes. It is one of the most valuable single molecules NZ could produce.

Estimated production requirement: NZ’s current aspirin consumption is modest (paracetamol is the preferred analgesic in NZ practice), but post-event demand would increase substantially as paracetamol stocks deplete. A rough estimate: 50–100 tonnes per year to supply NZ’s population at therapeutic levels for those who need it. This is achievable at industrial scale once the precursor chain is established, but years away.

3.2 Morphine extraction from opium poppies

What it is: Morphine is the most potent naturally occurring analgesic and remains the gold standard for severe pain management. It is extracted from the latex of opium poppies (Papaver somniferum).⁵⁴

Why this matters: When synthetic opioid stocks (fentanyl, oxycodone, tramadol) are depleted, morphine from opium poppies is the only source of strong analgesia available to NZ. Without strong analgesia, major surgery becomes unsafe — patient movement during incision and without muscle relaxation increases haemorrhage and injury risk, and pre-antibiotic-era surgical mortality was partly attributable to pain-related physiological shock. For cancer pain and end-of-life care, opioid absence removes the primary management tool and relegates palliative care to supportive measures only. Morphine production is therefore a direct surgical and palliative care enabler, not a comfort measure.

Legal framework: Opium poppy cultivation is currently illegal in NZ under the Misuse of Drugs Act 1975, except under licence. The government must establish a legal framework for controlled cultivation — modelled on the systems in Tasmania (Australia), where pharmaceutical opium poppies have been legally grown for decades, or on the Indian and Turkish government-controlled systems.⁵⁵ This requires:

• Designated growing areas (probably Canterbury Plains or Hawke’s Bay — suitable climate)
• Licensed growers under government contract
• All harvest delivered to a central processing facility
• No diversion to illicit use — security and enforcement
• International precedent provides detailed operational models

NZ suitability for opium poppy cultivation: Papaver somniferum grows in temperate climates with moderate rainfall. Canterbury and Hawke’s Bay have suitable conditions. The plant is frost-hardy, grows well in NZ’s soil types, and has been grown as an ornamental in NZ gardens (though latex-harvesting varieties are different from ornamental ones). Tasmania, with a similar climate to parts of NZ, is the world’s largest legal opium poppy producer — producing approximately 50% of the world’s legal opiate supply — demonstrating that Southern Hemisphere temperate climates are suitable.⁵⁶

Production process:

1. Cultivation. Sow poppy seeds in autumn or early spring. Growth period approximately 120 days to flowering. NZ’s growing season supports at least one crop per year.⁵⁷

2. Harvesting latex. Approximately 10–14 days after petal fall, score the unripe seed capsule with a multi-bladed knife. Latex (raw opium) oozes out and is collected after drying on the capsule surface. This is labour-intensive — each capsule must be scored individually. Yield: approximately 10–50 kg of raw opium per hectare, depending on variety, soil, and conditions.⁵⁸ Raw opium contains approximately 10–15% morphine by weight.⁵⁹

3. Extraction. Dissolve raw opium in water (morphine is water-soluble as a salt). Filter to remove plant debris. Add calcium hydroxide (lime water — Section 2.9) to precipitate calcium morphenate. Redissolve in dilute hydrochloric acid (from salt + sulfuric acid, see dependencies). Filter. Add ammonia to precipitate crude morphine base. Recrystallise to purify. Convert to morphine hydrochloride or morphine sulfate (the standard pharmaceutical salts) by dissolving in the appropriate acid and recrystallising.⁶⁰

4. For injectable use: Dissolve morphine salt in pyrogen-free water, filter through 0.22 micron sterile filters, fill into ampoules, autoclave. This requires sterile manufacturing capability.

5. For oral use: Tablet morphine salt with excipients (tableting equipment at Douglas Pharmaceuticals). Oral morphine is simpler to produce than injectable and adequate for many pain management applications.

Timeline:

• Year 0–1: Establish legal framework, identify growing areas, obtain seed stock (ornamental poppy growers in NZ may have suitable varieties; alternatively, import from Tasmania if maritime trade permits)
• Year 1–2: First cultivation trials. Learn optimal local growing conditions.
• Year 2–3: First harvest. Begin extraction chemistry development.
• Year 3–5: Scale up to meaningful production. Establish quality control.
• First useful quantities available approximately Year 3 — but with significant quality uncertainty initially.

Quality control: Morphine content of each batch must be determined before clinical use. Methods:

• UV spectrophotometry (if instruments available)
• Titration (acid-base titration can determine alkaloid content)
• Melting point (morphine base melts at 255°C — a basic purity check)
• Biological assay (in extremis — test potency on an animal model, though this is imprecise and ethically undesirable)

The quality control challenge is real. Inconsistent morphine content between batches is the primary safety risk — overdose from a batch with higher-than-expected concentration, or inadequate pain relief from a weak batch. Rigorous analytical testing of every batch is essential.

Codeine is also present in opium latex (approximately 1–3% of raw opium) and would be co-extracted. Codeine is a useful mild-to-moderate analgesic and cough suppressant. Additionally, morphine can be chemically converted to codeine by methylation, though this adds complexity.⁶¹

Feasibility: [B]. Opium poppy cultivation in NZ’s temperate climate is agronomically feasible — the crop is a known quantity in Southern Hemisphere conditions (see Tasmania’s industry). The extraction chemistry is well-documented. The main challenges are: regulatory (establishing the legal framework quickly); agronomic adaptation to NZ soil and pest conditions (requiring trial seasons before yields stabilise); and quality control (ensuring consistent morphine concentration in each extracted batch before clinical use). These are significant but tractable. Tasmania’s pharmaceutical opium industry demonstrates this is achievable in a comparable climate.⁶²

Medical value: Extremely high. Strong analgesia is a fundamental medical capability. Without it, surgery, trauma care, cancer palliation, and end-of-life care are severely compromised.

3.3 Chloroform (general anaesthetic and solvent)

What it is: Trichloromethane, historically used as a general anaesthetic (from the 1840s) and as a chemical solvent. Largely replaced in modern anaesthesia due to hepatotoxicity (liver damage) and a narrow therapeutic margin, but usable in the absence of alternatives.⁶³

Production process: Several routes:

• Haloform reaction: React ethanol or acetone with sodium hypochlorite (bleach). Sodium hypochlorite is produced by the chloralkali process (Doc #112). This is the simplest route if the chloralkali process is operational.
• Chlorination of methane: Requires methane (biogas — Doc #65) and chlorine gas. More complex and hazardous.

Quality control: Chloroform purity is important — impurities (particularly phosgene, which forms from chloroform oxidation) are extremely toxic. Chloroform must be stored with 0.5–1% ethanol, which acts as a stabiliser to prevent phosgene formation. Fresh production is safer than stored product.⁶⁴

Substitution performance gap: Chloroform anaesthesia carries a higher mortality risk than ether: approximately 1 in 3,000 administrations historically vs. approximately 1 in 5,000–15,000 for ether.⁶⁵ The narrower therapeutic margin (the ratio between effective and lethal doses) means overdose is more likely with inexperienced administrators. Additionally, chloroform causes hepatotoxicity with repeated exposure — anaesthetic staff or patients undergoing multiple procedures are at increased risk of liver damage. Chloroform should be reserved for situations where ether’s flammability is genuinely unacceptable (e.g., operating in environments with open flame that cannot be excluded). For routine use, ether is the lower-risk option.⁶⁶

Feasibility: [B]. Achievable once the chloralkali process is operational.

Medical value: Moderate. A backup anaesthetic when ether is unavailable or when fire risk prohibits ether use.

3.4 Penicillin — the hardest “achievable” drug

What it is and why it matters: Penicillin was the first antibiotic and remains one of the most important. It treats streptococcal and staphylococcal infections, pneumonia, wound infections, and many other bacterial diseases. When NZ’s stockpiled antibiotic supplies are depleted, the ability to produce even crude penicillin would save lives that would otherwise be lost to infection.⁶⁷

Why this section is long: Penicillin is the drug most frequently cited as “something NZ could make” in recovery planning discussions. It is technically possible. But the gap between “possible” and “safe, reliable, and useful” is where people die. This section is detailed because the details are where the real difficulty lies.

The biology: Penicillin is produced by the fungus Penicillium chrysogenum (formerly P. notatum) grown in liquid culture. The fungus secretes penicillin as a secondary metabolite — a chemical weapon against competing bacteria. Production requires growing the fungus under controlled conditions, extracting the penicillin from the culture broth, and purifying it to pharmaceutical grade.⁶⁸

What went wrong in the early days: The history of penicillin development is instructive. Fleming discovered penicillin in 1928. It took until 1942 — fourteen years, involving some of the best chemists and engineers in Britain and the United States, with massive wartime funding — before penicillin was produced in quantities sufficient for clinical use. The intermediate years were spent solving problems of yield, extraction, purification, and scale-up. The first patient treated with penicillin (Albert Alexander, 1941) died because there was not enough penicillin to complete the course of treatment. NZ does not have fourteen years of development time — but it also has the advantage of knowing what the solutions are.⁶⁹

Production process:

1. Obtain the organism. Penicillium chrysogenum is a common environmental mould — it is the blue-green mould that grows on bread and citrus fruit. However, wild strains produce very low yields of penicillin. High-yielding industrial strains have been developed through decades of mutation and selection. NZ may have industrial or laboratory strains in culture collections at universities (University of Otago, Massey University) or at ESR (Institute of Environmental Science and Research). If not, a wild strain can be isolated and used, but yields will be much lower.⁷⁰

2. Prepare culture medium. The fungus requires a nutrient broth containing:

   • A carbon source: lactose is optimal (available from NZ’s dairy industry — whey is a good source); glucose works but causes catabolite repression (lower penicillin yield)⁷¹
   • A nitrogen source: corn steep liquor was the historical breakthrough medium (and NZ grows maize, though in limited quantities); alternatives include yeast extract, soybean meal
   • Mineral salts: potassium phosphate, magnesium sulfate, trace elements
   • A precursor: phenylacetic acid (or phenoxyacetic acid) is added to direct biosynthesis toward the desired penicillin variant (penicillin G or penicillin V). Phenylacetic acid can be produced from toluene (petrochemical — problematic) or from certain fermentation pathways. Without it, the fungus produces a mixture of penicillin variants with lower overall yield and unpredictable clinical properties.⁷²
   • pH maintained at approximately 6.5–7.5

3. Fermentation. The fungus is grown in liquid culture at 25–27°C with aeration (penicillin production requires oxygen). In industry, this is done in large stirred, aerated fermentation vessels (fermenters). NZ’s dairy industry and brewing industry operate fermentation equipment that could potentially be adapted. The fermentation takes 5–7 days. During growth, the medium must be aerated, agitated, temperature-controlled, and monitored for pH and sterility.⁷³

   The sterility problem. The culture must not be contaminated with bacteria. Bacterial contamination (a) consumes the penicillin (many bacteria produce penicillinase, which destroys penicillin), (b) produces bacterial toxins that would contaminate the product, and (c) may outcompete the fungus. Maintaining sterility in a large fermentation vessel for 5–7 days requires steam sterilisation of the vessel and medium, sterile air filtration for aeration, and aseptic technique throughout. This is achievable in laboratory and industrial settings but requires trained personnel and validated equipment.⁷⁴

4. Extraction. After fermentation, the fungal biomass is removed by filtration. The penicillin is in the liquid broth. It is extracted by:

   • Acidifying the broth to pH 2–2.5 (penicillin becomes soluble in organic solvents at low pH)
   • Extracting into an organic solvent (butyl acetate or amyl acetate — these are themselves produced from acetic acid and butanol or amyl alcohol, adding to the dependency chain)
   • Back-extracting into aqueous buffer at neutral pH
   • Repeating to achieve purification
   • Final precipitation as a salt (potassium penicillin G or sodium penicillin G) by adding potassium acetate or sodium acetate in a suitable solvent⁷⁵

5. Drying. The precipitated penicillin salt is collected by filtration and dried under vacuum or by lyophilisation (freeze-drying). Freeze-dryers exist in NZ laboratories and hospitals (used for blood products).

6. Formulation. For injection: dissolve penicillin powder in sterile water immediately before use (penicillin is unstable in solution). For oral use: penicillin V (phenoxymethylpenicillin) is more acid-stable and can be given orally, but requires phenoxyacetic acid as a precursor, adding another dependency.

The quality control barrier — this is where the real difficulty lies:

Producing penicillin broth is not the hard part. Ensuring that what you produce is safe to inject into a human being is the hard part. The quality requirements are:

• Potency. Each batch must contain a known, consistent quantity of active penicillin. Under-dosing fails to treat the infection and promotes antibiotic resistance. Over-dosing can cause allergic reactions and toxicity. Potency is measured by bioassay (testing antibacterial activity against a standard organism — typically Staphylococcus aureus — on agar plates) or by chemical assay (HPLC, iodometric titration).⁷⁶

• Sterility. The final product must be sterile if it is to be injected. Sterility testing requires incubating samples in culture media for 14 days and confirming no growth. False negatives are possible (some contaminants grow slowly). The consequences of injecting a contaminated product are severe — sepsis and death.⁷⁷

• Pyrogen-free. The product must not contain bacterial endotoxins (pyrogens). Even if the product is sterile (live bacteria killed), dead bacterial cell wall fragments can cause fever, shock, and death. Pyrogen testing requires either the rabbit pyrogen test (inject into rabbits and monitor temperature) or the Limulus amebocyte lysate (LAL) test (which uses horseshoe crab blood extract — NZ does not have horseshoe crabs, and LAL reagent supplies are finite).⁷⁸

• No toxic contaminants. The fermentation broth may contain fungal toxins (mycotoxins), degradation products of penicillin (penicilloic acid, penillic acid — both can cause allergic reactions), and residual solvents from extraction. These must be below safety limits.⁷⁹

• Allergenic potential. Approximately 10% of the population reports penicillin allergy (though true IgE-mediated allergy is much less common). Impure penicillin preparations have higher rates of allergic reactions because the impurities (particularly penicilloylated proteins) are more allergenic than pure penicillin. Purer product means fewer allergic reactions.⁸⁰

The blunt assessment: A university laboratory or hospital pharmacy in NZ could produce crude penicillin within 1–2 years. Whether that product is safe to administer to patients is a different question entirely. The first batches will have uncertain potency, possible contaminants, and variable quality. Administering impure penicillin carries real risks: allergic reactions (including anaphylaxis), pyrogen reactions (fever, hypotension), and therapeutic failure from sub-potent batches. The question is whether these risks are acceptable compared to the alternative — untreated bacterial infections that are often fatal.

The pragmatic answer: Yes, in many cases the risk of crude penicillin is preferable to the certainty of death from untreated sepsis. But this is a clinical judgment that must be made case by case, not a blanket justification for distributing poorly quality-controlled product. Every effort must be made to improve quality with each production batch. The programme must be run by people who understand both the chemistry and the clinical risks.

Timeline:

• Year 1–2: Establish laboratory-scale production. Identify and cultivate the organism. Develop and validate the fermentation process. Begin quality testing protocols.
• Year 2–3: First clinical trials — initially topical application (wound washes, much lower risk than injection), then oral (if penicillin V precursors available), then injectable with rigorous quality control.
• Year 3–5: Scale up from laboratory flasks to pilot-scale fermenters. Improve yields and purity.
• Year 5–10: Establish production at useful scale (enough to supply NZ’s hospital system for serious infections).

Feasibility: [C]. The biology is achievable, but the quality control and precursor chemical requirements push this into [C] territory. Contaminated or sub-potent penicillin is a real risk, and it is not clear that NZ can solve the quality control problems without analytical instruments that will themselves be degrading.

Medical value: Extremely high — if the quality is adequate. The difference between having and not having antibiotics is one of the largest determinants of medical capability. Penicillin treats pneumonia, streptococcal infections, wound infections, meningitis (some forms), syphilis, and many other conditions. Without antibiotics, surgical mortality rises dramatically, and previously treatable infections become fatal.

3.5 Sulfonamide antibiotics

What they are: Sulfonamides were the first synthetic antibiotics, predating penicillin’s clinical use. Sulfanilamide (the simplest) is synthesised from aniline and chlorosulfonic acid. Sulfonamides are bacteriostatic (they stop bacterial growth rather than killing bacteria) and remain effective against urinary tract infections, some respiratory infections, and some wound infections.⁸¹

Why consider them: Sulfonamides are purely synthetic — no biological fermentation required. This eliminates the sterility and contamination risks of penicillin fermentation. The chemistry is more controllable. The tradeoff: sulfonamides are less potent than penicillin for most infections and have more side effects (allergic reactions, kidney damage at high doses, blood disorders rarely).

Production dependency chain:

1. Aniline — produced by nitration of benzene followed by reduction. Benzene comes from coal tar distillation (same dependency as phenol/aspirin). Nitration requires nitric acid (from ammonia oxidation — very difficult, see Doc #114 — or from sodium nitrate if obtainable). Reduction uses iron filings and hydrochloric acid (Bechamp reduction).⁸²
2. Chlorosulfonic acid — produced from sulfuric acid (Doc #113) and chlorine gas (chloralkali process, Doc #112). Extremely corrosive and hazardous to handle.⁸³
3. The synthesis then proceeds through acetanilide, p-acetamidobenzenesulfonyl chloride, and finally sulfanilamide.

Feasibility: [C]. Same coal tar dependency as aspirin. The synthesis is more complex and involves more hazardous reagents. But if NZ develops coal tar distillation, sulfonamide production becomes possible alongside aspirin.

Medical value: Moderate to high. Provides a synthetic antibiotic option that does not depend on biological fermentation.

3.6 Local anaesthetics (procaine)

What it is: Procaine (Novocaine) was the first widely used synthetic local anaesthetic. It enables pain-free dental work, minor surgery, and regional anaesthesia. When stockpiled lidocaine (the modern standard local anaesthetic) is depleted, procaine is the most realistic locally producible alternative.⁸⁴

Production dependency chain:

1. p-Aminobenzoic acid (PABA) — a starting material that can be produced from nitration and reduction of toluene (coal tar derivative) followed by oxidation.
2. 2-Diethylaminoethanol — requires ethanol and diethylamine (itself from ethanol and ammonia).
3. Esterification of PABA with 2-diethylaminoethanol under acid catalysis produces procaine.

Feasibility: [C]. Same industrial chemistry dependencies (coal tar, ammonia). If the broader chemical production infrastructure develops, procaine becomes feasible.

Medical value: High. Local anaesthesia is essential for dental care, wound suturing, and minor surgery. Without it, these procedures are performed on conscious, un-anaesthetised patients — which is both cruel and counterproductive (patient movement during surgery increases complications).

3.7 Catgut sutures

What it is: Surgical suture material made from the submucosa of sheep intestine (not actually from cats). Catgut is absorbable — the body gradually breaks it down, so the sutures do not need to be removed. It was the standard surgical suture material for centuries before synthetic absorbable sutures (Vicryl, Monocryl) replaced it.⁸⁵

Production process:

1. Obtain sheep intestine (NZ processes millions of sheep annually — intestine is readily available from meat works).
2. Strip the intestinal submucosa layer by soaking in dilute sodium hydroxide and scraping.
3. Twist or braid the submucosa strips into strands of desired thickness.
4. Treat with chromic acid (chrome-tanned catgut) for slower absorption, or leave plain for faster absorption.
5. Sterilise in chemical solution (formaldehyde or ethanol) or by irradiation.
6. Package in sterile containers.

Quality control: Tensile strength testing (each batch), sterility testing (standard microbiological methods), uniformity of diameter (caliper measurement).

Chromic acid dependency: Chromium compounds may be limited in NZ. Plain catgut (without chrome tanning) absorbs faster (5–10 days vs. 10–21 days) but is still usable.

Feasibility: [B]. NZ has the raw material in abundance. The production process is well-documented and requires modest chemistry. Quality control is achievable.

Medical value: High. Surgical sutures are consumable — every surgery uses them and they cannot be reused. When synthetic suture stocks are exhausted, catgut is the replacement.

---

4. TIER 3: NOT ACHIEVABLE FOR DECADES

This section is deliberately brief for each item because the essential message is the same: NZ lacks the industrial organic chemistry infrastructure to synthesise these molecules, and building that infrastructure requires decades of prior development.

4.1 Insulin

The problem: Insulin is a protein (51 amino acids, two polypeptide chains). Before recombinant DNA technology (1978 onwards), insulin was extracted from pig and cattle pancreases — the only pre-industrial production route. Even pancreatic extraction is difficult: it requires fresh pancreas tissue (available from NZ meat works), acid-alcohol extraction, multiple purification steps, crystallisation, and rigorous quality control.⁸⁶

Could NZ extract insulin from animal pancreases?

In principle, yes. The process was developed by Banting and Best in the 1920s and refined over subsequent decades. NZ’s meat processing industry discards millions of pig and cattle pancreases annually. The raw material exists.

In practice, the barriers are severe:

• Yield is low. One bovine pancreas yields approximately 100–200 units of insulin.⁸⁷ A typical Type 1 diabetes patient requires approximately 40–60 units per day.⁸⁸ This means one patient requires the pancreases from roughly one animal every 2–3 days, or approximately 120–180 animals per year.
• For NZ’s approximately 25,000 Type 1 patients: This would require approximately 3–4.5 million animal pancreases per year. NZ’s cattle and pig slaughter numbers could potentially supply this (NZ processes roughly 4.5 million cattle and 600,000 pigs annually), but it requires collecting pancreases from essentially every animal processed and directing them to insulin extraction — a massive logistical undertaking.⁸⁹
• Purification is the real problem. Crude animal insulin extracts contain other pancreatic proteins, enzymes (including destructive proteases), fats, and endotoxins. Purification to injectable grade historically required repeated crystallisation, chromatographic separation, and biological potency testing. The equipment and expertise for this are at the limit of what NZ could achieve.⁹⁰
• Allergenic reactions. Bovine insulin differs from human insulin by three amino acids; porcine insulin by one. These differences cause allergic reactions in some patients — approximately 5–10% of patients developed anti-insulin antibodies on animal insulin historically.⁹¹ This is manageable (switch species, use purified preparations) but adds complexity.
• Timeline. Optimistically, 3–5 years to produce crude animal insulin that could be used in emergencies. Realistically, 5–10 years to produce insulin of sufficient purity and consistency for routine clinical use.

Feasibility: [C/D]. This sits at the boundary of “difficult” and “long-term.” The raw materials exist, but the purification and quality control requirements are at the outer edge of what NZ can achieve without industrial chemistry infrastructure.

Medical value: Extreme. Approximately 25,000 NZers will die without insulin. This is the single most important pharmaceutical production challenge NZ faces. Any insulin production — even crude, even poorly purified — would extend lives that would otherwise end when stockpiled insulin is exhausted.

Recommendation: Begin animal insulin extraction research immediately (Phase 1), even though useful production is years away. Every month of earlier production saves lives. Partner with veterinary schools (Massey University) and chemistry departments. Investigate whether any NZ researchers have relevant experience — insulin purification biochemistry is a specialised skill.

4.2 Paracetamol (acetaminophen)

Why NZ can’t make it: Paracetamol synthesis requires p-aminophenol, which is produced from nitrobenzene or phenol via multiple steps — all dependent on the same coal tar / petrochemical infrastructure discussed under aspirin. But while aspirin can be made from salicylic acid via a relatively short synthesis, paracetamol’s synthesis is slightly more complex and requires an additional acetylation step with acetic anhydride. Given that aspirin is a reasonable analgesic substitute for most paracetamol indications, paracetamol production is lower priority than aspirin.⁹²

Feasibility: [C]. Same dependencies as aspirin, slightly more complex.

Medical value: Moderate. Aspirin substitutes for most paracetamol indications, though paracetamol has advantages for patients who cannot take aspirin (children with viral illness, patients with bleeding disorders, patients with aspirin allergy).

4.3 Modern antibiotics (beyond penicillin and sulfonamides)

Cephalosporins, macrolides (azithromycin, erythromycin), fluoroquinolones (ciprofloxacin), carbapenems, aminoglycosides (gentamicin): Each of these classes requires either complex fermentation with rare organisms, multi-step chemical modification of fermentation products, or total chemical synthesis of molecules far more complex than penicillin or sulfonamides. Even erythromycin, which is produced by fermentation (Saccharopolyspora erythraea), requires extraction and purification steps more complex than penicillin. Fluoroquinolones are entirely synthetic, requiring multiple steps with exotic reagents.⁹³

Feasibility: [D]. Not achievable without industrial organic chemistry. Decades away.

Medical value: Very high. Antibiotic resistance means that penicillin and sulfonamides will not treat all bacterial infections. Without broader-spectrum antibiotics, NZ’s medical capability is limited to what early-1940s medicine could do — which was a dramatic improvement over no antibiotics at all, but far less than modern practice.

4.4 Antivirals

Acyclovir, oseltamivir, tenofovir, antiretrovirals: Complex synthetic molecules. No realistic production pathway without industrial chemistry.

Feasibility: [D]. Not achievable.

Medical value: High for specific populations (HIV patients — NZ has approximately 3,000–4,000 people living with HIV).⁹⁴ Without antiretrovirals, HIV becomes fatal again. This is a hard truth.

4.5 Immunosuppressants

Cyclosporine, tacrolimus, mycophenolate: Cyclosporine is a fungal metabolite (from Tolypocladium inflatum), requiring specialised fermentation similar to penicillin but with an organism that is harder to culture and a product that is harder to purify. Tacrolimus is similarly a fermentation product (from Streptomyces tsukubaensis).⁹⁵

Feasibility: [D]. Not achievable.

Medical value: Critical for the approximately 3,000–4,000 transplant recipients in NZ. Without immunosuppressants, organ rejection occurs and is usually fatal. This is the starkest pharmaceutical rationing problem: a defined population with a certain timeline to death once their drugs run out.

4.6 Chemotherapy agents

Most cytotoxic drugs, targeted therapies, checkpoint inhibitors: Complex synthetic molecules or biologics. Far beyond NZ’s production capability.

Feasibility: [D]. Not achievable.

Medical value: Cancer treatment is effectively unavailable beyond whatever stockpiled drugs remain. Cancer care will revert to surgery (where possible) and palliative care. This will result in increased cancer mortality. For context, approximately 25,000 NZers are diagnosed with cancer each year, and cancer is the leading cause of death.⁹⁶

4.7 Vaccines

mRNA vaccines, recombinant vaccines, inactivated virus vaccines: Vaccine production requires either cell culture capability (growing viruses in cell lines — requires specialised media, incubators, and quality control), recombinant protein expression systems (E. coli or CHO cell culture with genetic engineering — far beyond NZ’s current capability), or inactivated virus production (growing live virus and then killing it — requires biosafety containment).⁹⁷

One partial exception: Jenner-style cowpox vaccination (live virus inoculation) for smallpox could theoretically be performed if smallpox re-emerged as a threat. But this is a very specific scenario.

Feasibility: [D]. Not achievable. NZ will depend on stockpiled vaccines until trade resumes or vaccine production technology is established — likely decades.

Medical value: Very high. Existing vaccination coverage protects currently immunised individuals, but herd immunity against measles requires approximately 95% coverage.⁹⁸ Each annual birth cohort (roughly 58,000–62,000 births in NZ) that receives no measles vaccine adds to the susceptible population. After 3–5 years without vaccination, the susceptible cohort reaches a size at which measles can circulate and establish epidemic transmission. Pre-vaccine measles case fatality rates in developed nations were approximately 1–2 per 1,000 cases in well-nourished populations, rising to 10–30% in malnourished populations — a realistic post-event scenario.⁹⁹ Pertussis and diphtheria follow a similar susceptibility accumulation trajectory. Vaccine stockpile management to extend coverage of birth cohorts as long as possible is addressed in Doc #116.

4.8 Essentially everything else in the modern formulary

Statins, ACE inhibitors, ARBs, proton pump inhibitors, SSRIs, SNRIs, benzodiazepines, atypical antipsychotics, calcium channel blockers, beta-blockers, direct oral anticoagulants, monoclonal antibodies — essentially the entire modern pharmaceutical armamentarium beyond what is listed in Tiers 1 and 2 — requires industrial organic chemistry or biological manufacturing that NZ will not possess for decades.

The honest summary: NZ’s pharmaceutical capability will resemble that of approximately 1920–1950 — morphine, ether, aspirin (eventually), crude penicillin (eventually), basic antiseptics, and not much else. This is not a temporary condition. It is the reality for Phase 2–5 at minimum (years 1–30), and possibly longer.

---

5. THE GAP: WHAT THIS MEANS FOR MEDICINE

Phase 2–5 (Years 1–30): This section describes the medical capability gap during the period when stockpiled pharmaceuticals are depleting and local production is developing. Conditions described here are most acute in Phase 2–3 (Years 1–7); by Phase 4–5, locally produced products (morphine, ether, penicillin, aspirin) partially close the gap.

5.1 What medicine can still do

Even without most of the modern formulary, medicine retains significant capability:

• Surgery. With ether anaesthesia, morphine analgesia, basic antisepsis, and (eventually) crude penicillin for post-operative infection, surgery remains viable for trauma, appendicitis, caesarean section, hernia repair, fracture fixation, amputation, and many other conditions. Surgical outcomes will be worse than modern standards — higher infection rates, higher mortality — but surgery will save lives.

• Obstetrics. Childbirth is managed with or without pharmaceuticals. Oxytocin for post-partum haemorrhage is a critical drug that NZ cannot produce (it is a peptide hormone, currently produced by chemical synthesis or recombinant methods). Manual management of post-partum haemorrhage and misoprostol (if available from stocks) are alternatives. Ergometrine (an ergot alkaloid) could theoretically be extracted from ergot fungus grown on rye, but this is complex and risky (ergot contains multiple toxic alkaloids).¹⁰⁰

• Wound care. Antiseptics (ethanol, iodine), wound irrigation (saline), dressing changes, debridement, and drainage remain the core of wound management. Antibiotics improve outcomes but are not the only tool.

• Pain management. Morphine, aspirin (eventually), non-pharmacological methods. Severe chronic pain management is the area of greatest loss.

• Public health. Sanitation, water treatment, quarantine, and hygiene measures prevent more disease than pharmaceuticals treat. Investment in public health infrastructure (clean water, sewage management, hand hygiene) has far more population-level impact than pharmaceutical production.

• Dental care. With local anaesthesia (procaine, eventually), dental care including extractions and basic fillings remains possible. Without local anaesthesia, extraction is the primary dental treatment — painful but effective for acute dental infection.

5.2 What medicine cannot do

• Manage chronic disease pharmacologically. Hypertension, diabetes (Type 1 and most Type 2), asthma, epilepsy, mental illness, autoimmune disease, chronic heart failure — all currently managed with daily medication — will be unmanageable once stockpiled drugs deplete. The health consequences include increased stroke, heart attack, diabetic emergencies, seizures, psychiatric crises, and asthma deaths. The magnitude of this effect is large: hundreds of thousands of NZers depend on daily medications that will not be available.

• Treat most cancers. Surgery and palliation only.

• Treat most viral infections. Supportive care only.

• Provide modern anaesthesia. Ether and chloroform are effective but crude compared to modern balanced anaesthesia (propofol induction, sevoflurane maintenance, neuromuscular blockade, opioid analgesia). Some surgical procedures that are routine under modern anaesthesia become impractical under ether.

• Prevent infectious disease in unvaccinated children. No new vaccine production. Existing pre-event vaccine stocks — if properly managed and cold-chained — may extend coverage to some post-event birth cohorts, but the duration depends heavily on stockpile depth at the time of the event and cold-chain integrity thereafter; this could range from under one year to several years.¹⁰¹ Once susceptible birth cohorts accumulate past the herd immunity threshold for measles (~95% coverage), epidemic circulation resumes.

• Maintain transplant recipients. Without immunosuppressants, organ rejection occurs over weeks to months.

5.3 The mortality impact

This section is speculative but important.

The withdrawal of modern pharmaceuticals will cause additional deaths. Estimating the number is fraught with uncertainty, but the categories include:

• Type 1 diabetes (approximately 22,000–25,000 patients): Without insulin, Type 1 diabetic patients develop diabetic ketoacidosis and die within days to weeks. Under aggressive rationing — including converting most Type 2 patients to oral agents — insulin stocks total approximately 320,000 patient-months (Doc #116, Section 9.3). Distributed equally, this lasts ~14 months for all Type 1 patients. Under age-weighted allocation, the same supply bridges approximately 5,000 children to domestic animal insulin production (320,000 / 5,000 ≈ 5 years), but 7,000–12,000 adult patients lose access within months (Doc #116, Section 9.5). Animal insulin extraction takes 3–5 years to achieve crude supply. The gap is unbridgeable for most adult patients regardless of rationing strategy.

• Transplant recipients (approximately 3,000–4,000): Without immunosuppressants, most will die within months to a few years of drug depletion.

• Cardiovascular disease: Withdrawal of antihypertensives, statins, and anticoagulants will increase stroke and heart attack rates. The magnitude is uncertain — lifestyle changes (increased physical activity, reduced caloric intake, reduced processed food) partially offset the loss of medication. Increase in cardiovascular mortality: possibly 10–30% above the baseline rate, which translates to hundreds to low thousands of additional deaths per year.¹⁰²

• Asthma and COPD: Withdrawal of inhalers increases exacerbation-related mortality. NZ has a disproportionately high asthma burden — approximately 600,000 people with asthma (roughly 12% of the population) and an asthma mortality rate historically among the highest in the OECD, at approximately 1.5–2.0 per 100,000 population per year even with modern treatment.¹⁰³ Without preventer inhalers (inhaled corticosteroids), exacerbation frequency and severity increase substantially; without reliever inhalers (salbutamol/albuterol), acute severe asthma becomes fatal at a higher rate.

• Cancer: Without chemotherapy and targeted therapy, five-year survival rates for many cancers decline dramatically. Additional cancer deaths: likely thousands per year.

• Infectious disease (as antibiotics deplete): Bacterial infections that are currently treatable become fatal. Surgical wound infections, pneumonia, urinary tract infections, dental infections with septic spread. Pre-antibiotic surgical mortality rates were approximately 10–30% for major operations; with penicillin they dropped below 5%. Reversion toward pre-antibiotic rates would mean additional thousands of deaths per year.¹⁰⁴

• Mental health: Withdrawal of psychiatric medications, combined with the immense psychosocial stress of the post-event environment, will likely increase suicide rates. This is addressed in Doc #122.

Total estimated excess mortality from pharmaceutical depletion: Unknown with any precision. Plausibly in the range of 5,000–15,000 additional deaths per year across all categories above, concentrated in the Phase 2–4 period (years 1–15) when stockpiled drugs are depleting and local production has not yet compensated. This is a rough estimate with wide uncertainty bounds. For context, NZ’s normal annual death rate is approximately 35,000.¹⁰⁵

---

6. STAGED DEVELOPMENT ROADMAP

6.1 Principles

1. Produce what saves the most lives per unit of effort first. Oral rehydration salts and ethanol antiseptic save more lives than attempting complex syntheses.
2. Build precursor industries that unlock multiple products. Sulfuric acid, caustic soda, and ethanol are prerequisites for many pharmaceutical and non-pharmaceutical products.
3. Quality control is essential. A poorly made drug is lethal, not just ineffective. Do not distribute products without adequate testing.
4. Capture expertise now. Identify every chemist, pharmacologist, pharmacist, and chemical engineer in NZ. Create the production development team in Phase 1, even though most production is years away.

6.2 Phase 1 (Months 0–12) — Foundation

Action	Responsibility	Priority
Establish Pharmaceutical Production Development Group (university chemists, pharmacists, Douglas Pharmaceuticals staff, Medsafe, chemical engineers)	Ministry of Health + universities	Immediate
Inventory all chemical reagents, glassware, and laboratory equipment in NZ universities, hospitals, and commercial labs	Development Group	First 30 days
Identify and secure Penicillium chrysogenum culture strains from NZ collections	University of Otago, Massey	First 30 days
Scale up ethanol production at existing distilleries for pharmaceutical use	MPI + distillers	First 3 months
Begin producing ORS sachets at hospital pharmacies and distribute	Te Whatu Ora	First month
Begin iodine extraction trials from coastal kelp	Development Group + coastal communities	First 6 months
Establish legal framework for opium poppy cultivation	MoH + MoJ + Parliament	First 6 months
Obtain opium poppy seed for first trial cultivation	Through agricultural networks	First 6 months
Begin animal insulin extraction research at Massey University	Development Group	Immediate
Preserve all laboratory analytical instruments — restrict use, maintain carefully, stockpile replacement parts	Universities + hospitals	Immediate

6.3 Phase 2 (Years 1–3) — First Production

Action	Timeline
Ethanol available at pharmaceutical quality for antiseptic use	Year 1
Iodine tincture production from seaweed operational	Year 1–2
Basic IV saline production at hospital pharmacies at useful scale	Year 1–2
First opium poppy crop planted	Year 1
Ether production begins (once sulfuric acid available — Doc #113)	Year 2–3
First penicillin fermentation trials in laboratory	Year 1–2
Catgut suture production trials at meat works	Year 1–2
Animal insulin extraction research yields first crude extracts	Year 2–3
Activated charcoal production operational	Year 1

6.4 Phase 3 (Years 3–7) — Scaling Up

Action	Timeline
First morphine extraction from opium poppy harvest	Year 3–4
Morphine available for hospital use (oral first, then injectable)	Year 4–5
Penicillin quality improving — first clinical use (topical, then oral/injectable)	Year 3–5
Chloroform production operational	Year 3–5
Coal tar distillation begins (tied to steel industry — Doc #89)	Year 5+
Aspirin production begins (once phenol available from coal tar)	Year 5–7
Animal insulin extraction at pilot scale	Year 5–7
Catgut suture production at useful scale	Year 3–5

6.5 Phase 4–5 (Years 7–30) — Industrial Chemistry Develops

Action	Timeline
Aspirin production at national scale	Year 7–10
Sulfonamide antibiotic production begins	Year 7–10
Procaine (local anaesthetic) production begins	Year 7–10
Penicillin production at reliable quality and useful scale	Year 7–10
Animal insulin production at semi-industrial scale	Year 10–15
First trade-acquired modern pharmaceuticals from Australia, Brazil, or other regions	Year 10–20 (highly uncertain)

6.6 Phase 6–7 (Years 30+) — Long-term

Possibility	Notes
Broader antibiotic production (erythromycin, cephalosporins)	Depends on industrial fermentation capability
Synthetic pharmaceutical production from petrochemical or coal-chemical base	Depends on broader industrial chemistry development
Vaccine production	Depends on biotechnology capability — possibly imported first
Recombinant insulin	Requires genetic engineering and cell culture technology — decades

---

7. CRITICAL UNCERTAINTIES

Uncertainty	Impact if wrong	Resolution
Availability of phenol from coal tar	If NZ does not develop coal tar distillation, aspirin, sulfonamides, and procaine are all unavailable	Linked to steel industry development (Doc #89). Alternative phenol sources (biosynthesis) are speculative
Penicillin quality achievable without advanced analytical instruments	If quality control is inadequate, crude penicillin may harm rather than help	Begin quality testing protocols early; ration analytical instrument use for pharmaceutical QC; develop simpler bioassay methods
Animal insulin extraction feasibility	If purification cannot be achieved, Type 1 diabetes patients have no insulin source	Begin research immediately; partner with international expertise if trade permits
Sulfuric acid availability (Doc #113)	Without sulfuric acid, ether, chloroform, aspirin, and many other products are not producible	Sulfuric acid production is a prerequisite industry
Opium poppy yield in NZ conditions	If NZ’s climate or soil produces low alkaloid yields, morphine supply is limited	Trial cultivation in multiple regions; learn from Tasmanian experience
Skilled personnel availability	If key chemists and pharmacists die, retire, or are allocated to other tasks, the production programme stalls	Identify and protect key personnel early; begin training apprentices immediately
Analytical instrument longevity	Quality control degrades as instruments fail	Prioritise instrument maintenance; develop low-tech analytical alternatives
Trade development timeline	If trade with Australia/Brazil develops early, some pharmaceutical imports become available; if not, NZ is on its own	Plan as though NZ is on its own; benefit from trade if it materialises

---

8. RONGOĀ MĀORI AS COMPLEMENT TO LOCAL PRODUCTION

Rongoā Māori (traditional Māori plant medicine) does not depend on industrial chemistry and is available from Phase 1 onward. Its role grows in relative importance as modern pharmaceutical stocks deplete. However, rongoā does not replace the local pharmaceutical production described in this document — it addresses a different and narrower range of conditions (mild pain, minor wounds, mild respiratory and GI symptoms). See Doc #4, Section 9.1 for the detailed rongoā species table, evidence assessment, and integration protocol. The key point for this document is that mānuka honey wound management — clinically validated, NZ-produced, and immediately available — is the highest-value rongoā application, directly reducing demand on imported antiseptic and wound care supplies that this document’s production programme cannot replicate in the near term.¹⁰⁶¹⁰⁷

---

Cross-References

Pharmaceutical production has deep chemical dependency chains. The documents below are direct dependencies or close companions. None of the Tier 2 or Tier 3 production described in this document is achievable without the precursor industries covered in the chemical infrastructure documents listed here.

• Doc #116 — Pharmaceutical Rationing and Shelf-Life Extension — Companion document. Doc #116 covers extending existing stockpiles; this document covers what comes after stockpiles are exhausted. The two must be read together — rationing buys time for local production to mature.

• Doc #020 — Pharmaceutical Reference — Reference formulary for practitioners operating without modern supply. Identifies which drugs can be substituted, which are irreplaceable, and how to manage drug class by drug class under scarcity.

• Doc #004 — Medical Supply — Covers the broader medical consumables picture. Pharmaceutical production does not exist in isolation — syringes, needles, dressings, and other consumables must also be locally produced or stockpiled.

• Doc #113 — Sulfuric Acid — Direct prerequisite. Sulfuric acid is required for ether production (Section 2.4), aspirin synthesis (Section 3.1), sulfonamide antibiotics (Section 3.5), and hydrochloric acid production (needed for morphine extraction, Section 3.2). No pharmaceutical production programme advances to Tier 2 without this.

• Doc #114 — Ammonia — Required for sulfonamide antibiotic synthesis (Section 3.5) and local anaesthetic production (procaine, Section 3.6). Ammonia synthesis is one of the most technically demanding industrial chemistry problems NZ faces.

• Doc #112 — Lime/Caustic Soda — Caustic soda (sodium hydroxide) is a prerequisite chemical appearing throughout this document: soap production (Section 2.8), catgut processing (Section 3.7), aspirin synthesis (Section 3.1), and morphine extraction (Section 3.2). The chloralkali process also produces chlorine gas, needed for chloroform (Section 3.3).

• Doc #111 — Methanol — Methanol is a potential solvent and feedstock in several pharmaceutical synthesis pathways, including acetic acid production routes relevant to aspirin synthesis. Methanol availability also affects which organic chemistry pathways are accessible.

• Doc #102 — Charcoal — Source document for activated charcoal production (Section 2.7). Activated charcoal is both a pharmaceutical product in its own right (oral poisoning treatment) and a component of some purification processes in pharmaceutical manufacturing.

• Doc #098 — Glass Production — Laboratory glassware is a finite and irreplaceable resource. Ampoules, vials, flasks, condensers, and reaction vessels are all required throughout this document. When existing borosilicate stock fails and cannot be replaced, pharmaceutical quality control and many production processes become impossible. This dependency is one of the hardest long-term constraints on the entire programme.

---

APPENDIX A: SUMMARY TABLE — LOCAL PHARMACEUTICAL PRODUCTION CAPABILITY

Product	Feasibility	Timeline	Key dependencies	Medical value
Oral rehydration salts	[A]	Immediate	Salt, sugar, potassium chloride	High
Ethanol (antiseptic)	[A]	Months	Fermentable carbohydrate, distillation equipment	High
Soap	[A]	Months	Tallow, caustic soda	Very high
Activated charcoal	[A]	Months	Wood, heat	Moderate
Lime water	[A]	Immediate	Limestone	Low–moderate
Basic IV saline	[B]	Year 1–2	Salt, distilled water, sterile containers, autoclave	Very high
Iodine tincture	[A/B]	Year 1–2	Seaweed, ethanol, sulfuric acid	High
Zinc oxide paste	[B]	Year 1–3	Zinc (limited NZ supply), lanolin	Moderate
Ether (anaesthetic)	[B]	Year 2–3	Ethanol, sulfuric acid (Doc #113)	High
Chloroform (anaesthetic)	[B]	Year 2–3	Ethanol or acetone, sodium hypochlorite (Doc #112)	Moderate
Catgut sutures	[B]	Year 2–3	Sheep intestine, sodium hydroxide	High
Morphine (from opium poppy)	[B]	Year 3–5	Arable land, seed stock, HCl, extraction equipment	Extremely high
Crude penicillin	[C]	Year 3–7	Penicillium strain, fermentation equipment, quality control	Extremely high (if quality adequate)
Aspirin	[C]	Year 5–10	Phenol (from coal tar), caustic soda, CO2, acetic anhydride, pressure vessel	Very high
Sulfonamide antibiotics	[C]	Year 7–10	Aniline (from coal tar), chlorosulfonic acid	Moderate–high
Procaine (local anaesthetic)	[C]	Year 7–10	PABA (from coal tar), diethylaminoethanol	High
Animal insulin	[C/D]	Year 5–15	Animal pancreas, purification chemistry	Extreme
Paracetamol	[C]	Year 5–10	p-Aminophenol (from coal tar), acetic anhydride	Moderate
Modern antibiotics	[D]	Decades	Industrial organic chemistry	Very high
Antivirals	[D]	Decades	Industrial organic chemistry	High
Immunosuppressants	[D]	Decades	Industrial fermentation / organic chemistry	Critical (small pop.)
Vaccines	[D]	Decades	Cell culture, biotechnology	Very high
Insulin (recombinant)	[D]	Decades	Genetic engineering, cell culture	Extreme

---

APPENDIX B: PRECURSOR CHEMICAL REQUIREMENTS

The following chemicals are prerequisites for pharmaceutical production. Each must be available before the products that depend on them can be made.

Precursor	Source in NZ	Products it enables	Status
Ethanol	Fermentation + distillation	Antiseptic, ether, chloroform, tinctures, solvent	Available — scale up existing
Sulfuric acid	Geothermal sulfur (Doc #113)	Ether, aspirin, sulfonamides, HCl, many processes	Must be established
Sodium hydroxide (caustic soda)	Chloralkali process from brine (Doc #112)	Soap, aspirin, catgut processing, many processes	Must be established
Hydrochloric acid	Salt + sulfuric acid	Morphine extraction, various purifications	Depends on sulfuric acid
Phenol	Coal tar distillation	Aspirin, carbolic acid antiseptic	Depends on coal coking
Acetic acid	Fermentation (vinegar)	Acetic anhydride (for aspirin)	Available — scale up
Acetic anhydride	From acetic acid	Aspirin, paracetamol	Must be established
Calcium hydroxide (lime)	Limestone	Morphine extraction, water treatment, antacid	Available
Chlorine gas	Chloralkali process (Doc #112)	Chloroform, water treatment, bleach	Depends on chloralkali
Carbon dioxide	Fermentation byproduct, limestone calcination	Kolbe-Schmitt reaction (aspirin)	Available
Lactose	Dairy whey	Penicillin fermentation medium	Available

---

---

1. University of Otago School of Pharmacy (https://www.otago.ac.nz/pharmacy) and University of Auckland School of Pharmacy (https://www.auckland.ac.nz/en/fmhs/about/school-of-pharma...) are NZ’s two pharmacy schools. Both have pharmaceutical chemistry and analytical laboratories. Chemistry departments at all NZ universities have organic synthesis and analytical capability.↩︎

2. University of Otago School of Pharmacy (https://www.otago.ac.nz/pharmacy) and University of Auckland School of Pharmacy (https://www.auckland.ac.nz/en/fmhs/about/school-of-pharma...) are NZ’s two pharmacy schools. Both have pharmaceutical chemistry and analytical laboratories. Chemistry departments at all NZ universities have organic synthesis and analytical capability.↩︎

3. NZ has multiple distilleries producing spirits from grain and fruit fermentation. See also: Doc #56 (Wood Gasification) for ethanol production from wood-derived sugars. Whey-based ethanol is a natural byproduct of NZ’s dairy industry. Fonterra and other dairy processors have explored whey ethanol as a fuel.↩︎

4. NZ’s Taupo Volcanic Zone has geothermal sulfur deposits. Sulfur is deposited around fumaroles and hot springs in the Rotorua-Taupo region. The Wairakei and Ohaaki geothermal fields produce hydrogen sulfide, from which elemental sulfur can be recovered. See Doc #113 for sulfuric acid production from NZ sulfur.↩︎

5. NZ has abundant limestone (calcium carbonate) deposits. Major quarries: Oparure (Waikato), McDonald’s Lime (Otorohanga), various South Island operations. See Doc #112. Limestone is also the feedstock for cement production.↩︎

6. Dominion Salt operates NZ’s only solar salt works at Lake Grassmere, Marlborough, producing approximately 50,000–70,000 tonnes of salt per year. Additional salt can be produced by solar evaporation of seawater at coastal sites.↩︎

7. Brown algae (kelp) species around NZ contain iodine concentrated from seawater. Iodine content varies: Macrocystis pyrifera and Ecklonia radiata are NZ species with moderate iodine content. Historical iodine production from kelp was practiced in Scotland, France, and Japan before mineral iodine sources were exploited. See: Mouritsen OG, “Seaweeds: Edible, Available, and Sustainable,” University of Chicago Press, 2013.↩︎

8. NZ’s meat processing industry produces approximately 100,000–150,000 tonnes of tallow per year (estimate based on livestock processing volumes). Tallow is the primary NZ feedstock for soap production and biodiesel. See also Doc #34 (Lubricant Production).↩︎

9. NZ has limited zinc mineralisation. Some polymetallic deposits exist (e.g., in the Coromandel region), but NZ is not a commercial zinc producer. Zinc availability for pharmaceutical use (zinc oxide) is likely to come from recycled/stockpiled material rather than mining.↩︎

10. Stats NZ / Beef + Lamb New Zealand. NZ has approximately 26 million sheep and 10 million cattle. Annual livestock processing provides raw materials including intestine (catgut), tallow (soap), lanolin (excipient), and pancreas (insulin extraction). Pig slaughter is approximately 600,000–700,000 per year.↩︎

11. Douglas Pharmaceuticals (https://www.douglas.co.nz/) operates pharmaceutical manufacturing facilities in Auckland with tableting, encapsulation, and packaging capability. The facility produces finished dose forms from imported APIs. Infrastructure includes clean rooms, stability testing, and quality control laboratories.↩︎

12. Marsden Point Oil Refinery (Refining NZ, now Channel Infrastructure) ceased oil refining operations in 2022 and converted to an import-only fuel terminal. NZ no longer has domestic oil refining capability. This eliminates the most common source of petrochemical feedstocks (benzene, toluene, phenol from crude oil cracking).↩︎

13. NZ has no significant organic chemical synthesis industry. The country imports essentially all organic chemicals used in manufacturing, agriculture, and pharmaceuticals. This is a fundamental constraint on pharmaceutical production.↩︎

14. NZ’s Taupo Volcanic Zone has geothermal sulfur deposits. Sulfur is deposited around fumaroles and hot springs in the Rotorua-Taupo region. The Wairakei and Ohaaki geothermal fields produce hydrogen sulfide, from which elemental sulfur can be recovered. See Doc #113 for sulfuric acid production from NZ sulfur.↩︎

15. Hydrochloric acid is produced industrially by the Mannheim process: sodium chloride + sulfuric acid, heated to yield sodium sulfate + HCl gas, which is dissolved in water. This requires sulfuric acid production (Doc #113) and salt.↩︎

16. O-I Glass NZ (https://www.o-i.com/) operates a glass manufacturing plant in Auckland producing container glass (bottles, jars). Borosilicate glass (Pyrex-type, used for laboratory glassware and pharmaceutical vials) requires boron compounds (borax) that NZ does not produce. NZ does have some borosilicate glassware in existing laboratories — this is a finite, irreplaceable resource.↩︎

17. Sterile pharmaceutical manufacturing requires: clean room with HEPA-filtered air (ISO Class 5–7), sterile filling equipment, autoclaves for terminal sterilisation, validated processes, and trained staff. NZ’s hospital compounding pharmacies and Douglas Pharmaceuticals have some of this capability, but scaling to national supply levels requires significant expansion.↩︎

18. Coal tar is a byproduct of coal coking (heating coal in the absence of air to produce coke for steelmaking). Fractional distillation of coal tar yields: light oils (benzene, toluene), middle oils (phenol, cresols, naphthalene), heavy oils (anthracene), and pitch. Phenol from coal tar was the original source before petroleum-based production. See: Speight JG, “The Chemistry and Technology of Coal,” CRC Press, 2012.↩︎

19. Acetic anhydride can be produced by the ketene route: dehydrate acetic acid over a catalyst at high temperature to produce ketene gas, then react ketene with acetic acid to produce acetic anhydride. This requires specialised high-temperature reactors. Alternative routes exist but are similarly complex. See: Weissermel K and Arpe H-J, “Industrial Organic Chemistry,” Wiley-VCH, 2003.↩︎

20. The chloralkali process electrolyses brine (sodium chloride solution) to produce sodium hydroxide, chlorine gas, and hydrogen gas. NZ has salt (Lake Grassmere) and electricity (renewable grid). See Doc #112 (Lime and Caustic Soda) for NZ-specific implementation.↩︎

21. WHO/UNICEF oral rehydration salts (ORS) formulation: sodium chloride 2.6 g/L, potassium chloride 1.5 g/L, trisodium citrate dihydrate 2.9 g/L, glucose anhydrous 13.5 g/L. Dissolved in 1 litre of clean water. See: WHO, “The Treatment of Diarrhoea: A Manual for Physicians and Other Senior Health Workers,” 2005.↩︎

22. ORS concentration accuracy: the WHO low-osmolarity ORS formula has a narrow therapeutic window. Solutions with sodium concentrations significantly above the target can cause hypernatraemic dehydration, which is more dangerous than the original diarrhoeal illness in young children. See: Hahn S et al., “Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children,” Cochrane Database of Systematic Reviews, 2002. Field production must use calibrated measuring equipment, not estimation by volume of “pinches” or “handfuls.”↩︎

23. ORS concentration accuracy: the WHO low-osmolarity ORS formula has a narrow therapeutic window. Solutions with sodium concentrations significantly above the target can cause hypernatraemic dehydration, which is more dangerous than the original diarrhoeal illness in young children. See: Hahn S et al., “Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children,” Cochrane Database of Systematic Reviews, 2002. Field production must use calibrated measuring equipment, not estimation by volume of “pinches” or “handfuls.”↩︎

24. NZ has multiple distilleries producing spirits from grain and fruit fermentation. See also: Doc #56 (Wood Gasification) for ethanol production from wood-derived sugars. Whey-based ethanol is a natural byproduct of NZ’s dairy industry. Fonterra and other dairy processors have explored whey ethanol as a fuel.↩︎

25. Whey contains approximately 4.5–5% lactose. Fonterra and other NZ dairy processors generate large volumes of whey as a byproduct of cheese and casein manufacture. Lactose can be fermented to ethanol using Kluyveromyces marxianus yeast. Some NZ-based research has explored whey-to-ethanol processes.↩︎

26. Methanol contamination in distilled spirits is managed by discarding the foreshots (first fraction of distillate, which concentrates methanol and other volatile compounds). This is standard distilling practice. Grain- and sugar-based fermentations produce minimal methanol; fruit-based fermentations (especially apple/pear) produce more due to pectin content.↩︎

27. Sterile IV fluid production: see USP (United States Pharmacopeia) chapters on sterile preparations. Pyrogen testing: LAL (Limulus Amebocyte Lysate) test or rabbit pyrogen test. Pyrogen-free water is produced by distillation — not by filtration alone, as endotoxins can pass through standard filters.↩︎

28. Sterile IV fluid production: see USP (United States Pharmacopeia) chapters on sterile preparations. Pyrogen testing: LAL (Limulus Amebocyte Lysate) test or rabbit pyrogen test. Pyrogen-free water is produced by distillation — not by filtration alone, as endotoxins can pass through standard filters.↩︎

29. Diethyl ether was the first widely used general anaesthetic (first public demonstration: William Morton, Massachusetts General Hospital, 1846). It remains effective and is still used in some developing countries. See: Dundee JW, “A History of Anaesthesia,” Cambridge University Press. Ether anaesthesia provides good muscle relaxation and maintains blood pressure but has slow induction, causes nausea, and is extremely flammable.↩︎

30. Diethyl ether was the first widely used general anaesthetic (first public demonstration: William Morton, Massachusetts General Hospital, 1846). It remains effective and is still used in some developing countries. See: Dundee JW, “A History of Anaesthesia,” Cambridge University Press. Ether anaesthesia provides good muscle relaxation and maintains blood pressure but has slow induction, causes nausea, and is extremely flammable.↩︎

31. Diethyl ether was the first widely used general anaesthetic (first public demonstration: William Morton, Massachusetts General Hospital, 1846). It remains effective and is still used in some developing countries. See: Dundee JW, “A History of Anaesthesia,” Cambridge University Press. Ether anaesthesia provides good muscle relaxation and maintains blood pressure but has slow induction, causes nausea, and is extremely flammable.↩︎

32. Diethyl ether was the first widely used general anaesthetic (first public demonstration: William Morton, Massachusetts General Hospital, 1846). It remains effective and is still used in some developing countries. See: Dundee JW, “A History of Anaesthesia,” Cambridge University Press. Ether anaesthesia provides good muscle relaxation and maintains blood pressure but has slow induction, causes nausea, and is extremely flammable.↩︎

33. Iodine was discovered in seaweed ash by Bernard Courtois in 1811. Tincture of iodine (iodine in ethanol) has been used as a wound antiseptic since the 1830s. It is effective against bacteria, viruses, fungi, and spores. The iodine-from-kelp industry operated commercially in Scotland, France, and Japan through the 19th century.↩︎

34. Brown algae (kelp) species around NZ contain iodine concentrated from seawater. Iodine content varies: Macrocystis pyrifera and Ecklonia radiata are NZ species with moderate iodine content. Historical iodine production from kelp was practiced in Scotland, France, and Japan before mineral iodine sources were exploited. See: Mouritsen OG, “Seaweeds: Edible, Available, and Sustainable,” University of Chicago Press, 2013.↩︎

35. Brown algae (kelp) species around NZ contain iodine concentrated from seawater. Iodine content varies: Macrocystis pyrifera and Ecklonia radiata are NZ species with moderate iodine content. Historical iodine production from kelp was practiced in Scotland, France, and Japan before mineral iodine sources were exploited. See: Mouritsen OG, “Seaweeds: Edible, Available, and Sustainable,” University of Chicago Press, 2013.↩︎

36. Iodine was discovered in seaweed ash by Bernard Courtois in 1811. Tincture of iodine (iodine in ethanol) has been used as a wound antiseptic since the 1830s. It is effective against bacteria, viruses, fungi, and spores. The iodine-from-kelp industry operated commercially in Scotland, France, and Japan through the 19th century.↩︎

37. Zinc oxide has mild antimicrobial and wound-healing properties and has been used in wound care for centuries. It is a component of calamine lotion (zinc oxide + iron oxide) and various barrier creams. See: Jones V et al., “The role of zinc oxide in wound healing,” BMC Dermatology, 2015.↩︎

38. NZ is one of the world’s largest producers of lanolin (wool grease), extracted during the wool scouring process. Lanolin is a complex mixture of esters, used as an excipient (base for creams and ointments) and emollient. NZ’s wool scouring industry (primarily Canterbury) produces approximately 1,500–2,000 tonnes per year.↩︎

39. NZ has limited zinc mineralisation. Some polymetallic deposits exist (e.g., in the Coromandel region), but NZ is not a commercial zinc producer. Zinc availability for pharmaceutical use (zinc oxide) is likely to come from recycled/stockpiled material rather than mining.↩︎

40. Activated charcoal is the standard treatment for acute oral poisoning (adsorbs toxins in the GI tract). Also used for water purification. Production: pyrolyse wood to charcoal, then activate by heating in steam or CO2 at 800–1000°C. See: Marsh H and Rodriguez-Reinoso F, “Activated Carbon,” Elsevier, 2006.↩︎

41. Activated charcoal is the standard treatment for acute oral poisoning (adsorbs toxins in the GI tract). Also used for water purification. Production: pyrolyse wood to charcoal, then activate by heating in steam or CO2 at 800–1000°C. See: Marsh H and Rodriguez-Reinoso F, “Activated Carbon,” Elsevier, 2006.↩︎

42. Handwashing with soap is more effective at reducing disease transmission than alcohol-based hand sanitisers for many pathogens, and far more effective than no hand hygiene. See: Aiello AE et al., “Effect of hand hygiene on infectious disease risk in the community setting: a meta-analysis,” American Journal of Public Health, 2008.↩︎

43. NZ has abundant limestone (calcium carbonate) deposits. Major quarries: Oparure (Waikato), McDonald’s Lime (Otorohanga), various South Island operations. See Doc #112. Limestone is also the feedstock for cement production.↩︎

44. Lime kiln fuel requirements: traditional wood-fired kilns consume approximately 3–5 tonnes of wood fuel per tonne of quicklime produced, depending on kiln design and wood moisture content. Lime calcination temperature: 900–1000°C for complete conversion of CaCO3 to CaO. Under-firing produces “dead-burned” lime with reduced reactivity. See: Boynton RS, “Chemistry and Technology of Lime and Limestone,” Wiley-Interscience, 1980.↩︎

45. NZ has abundant limestone (calcium carbonate) deposits. Major quarries: Oparure (Waikato), McDonald’s Lime (Otorohanga), various South Island operations. See Doc #112. Limestone is also the feedstock for cement production.↩︎

46. Aspirin (acetylsalicylic acid) was first synthesised by Felix Hoffmann at Bayer in 1897. It remains one of the most widely used and most important drugs in history. Its mechanisms include anti-inflammatory (COX-1 and COX-2 inhibition), analgesic, antipyretic, and antiplatelet effects.↩︎

47. Willow bark (Salix species) contains salicin at concentrations of approximately 1–12% by dry weight, varying by species, season, and individual plant. Standardised dosing is not achievable from raw bark preparations. See: Shara M and Stohs SJ, “Efficacy and Safety of White Willow Bark Extract,” Phytotherapy Research, 2015.↩︎

48. Willow bark (Salix species) contains salicin at concentrations of approximately 1–12% by dry weight, varying by species, season, and individual plant. Standardised dosing is not achievable from raw bark preparations. See: Shara M and Stohs SJ, “Efficacy and Safety of White Willow Bark Extract,” Phytotherapy Research, 2015.↩︎

49. Coal tar is a byproduct of coal coking (heating coal in the absence of air to produce coke for steelmaking). Fractional distillation of coal tar yields: light oils (benzene, toluene), middle oils (phenol, cresols, naphthalene), heavy oils (anthracene), and pitch. Phenol from coal tar was the original source before petroleum-based production. See: Speight JG, “The Chemistry and Technology of Coal,” CRC Press, 2012.↩︎

50. Biosynthetic routes to phenol from glucose via engineered microorganisms are an active area of academic research. As of 2025, no commercially viable biosynthetic phenol process exists. See: Kim B et al., “Metabolic engineering of Escherichia coli for the production of phenol from glucose,” Biotechnology Journal, 2014.↩︎

51. The Kolbe-Schmitt reaction: sodium phenoxide + CO2 under pressure (100–150 atm, 125°C) yields sodium salicylate. First described by Hermann Kolbe and Rudolf Schmitt in 1860. The reaction requires a pressure vessel capable of withstanding high pressures and temperatures. Well-established industrial chemistry; any organic chemistry text describes the mechanism.↩︎

52. Aspirin (acetylsalicylic acid) was first synthesised by Felix Hoffmann at Bayer in 1897. It remains one of the most widely used and most important drugs in history. Its mechanisms include anti-inflammatory (COX-1 and COX-2 inhibition), analgesic, antipyretic, and antiplatelet effects.↩︎

53. Acetic anhydride can be produced by the ketene route: dehydrate acetic acid over a catalyst at high temperature to produce ketene gas, then react ketene with acetic acid to produce acetic anhydride. This requires specialised high-temperature reactors. Alternative routes exist but are similarly complex. See: Weissermel K and Arpe H-J, “Industrial Organic Chemistry,” Wiley-VCH, 2003.↩︎

54. Morphine is the principal alkaloid of opium (10–15% by weight of raw opium). Other alkaloids present include codeine (1–3%), thebaine (1–2%), and papaverine (0.5–1%). Extraction involves dissolution in water, precipitation with lime, acid/base manipulations. See: Moffat AC, “Clarke’s Analysis of Drugs and Poisons,” Pharmaceutical Press.↩︎

55. Tasmania (Australia) produces approximately 50% of the world’s legal opiates, from Papaver somniferum varieties bred for high morphine or thebaine content. The Tasmanian industry operates under strict government licensing (Poppy Advisory and Control Board). See: Tasmania Department of Primary Industries, Parks, Water and Environment — Alkaloid Poppy Industry. The Indian and Turkish systems provide additional models for government-controlled opium production.↩︎

56. Tasmania (Australia) produces approximately 50% of the world’s legal opiates, from Papaver somniferum varieties bred for high morphine or thebaine content. The Tasmanian industry operates under strict government licensing (Poppy Advisory and Control Board). See: Tasmania Department of Primary Industries, Parks, Water and Environment — Alkaloid Poppy Industry. The Indian and Turkish systems provide additional models for government-controlled opium production.↩︎

57. Papaver somniferum agronomics: 120 days from sowing to harvest. Yields 10–50 kg raw opium per hectare depending on variety, climate, and technique. Seeds sown at 1–2 kg/ha. Prefers well-drained, slightly alkaline soil. Frost-tolerant. Canterbury Plains and Hawke’s Bay have suitable conditions.↩︎

58. Papaver somniferum agronomics: 120 days from sowing to harvest. Yields 10–50 kg raw opium per hectare depending on variety, climate, and technique. Seeds sown at 1–2 kg/ha. Prefers well-drained, slightly alkaline soil. Frost-tolerant. Canterbury Plains and Hawke’s Bay have suitable conditions.↩︎

59. Morphine is the principal alkaloid of opium (10–15% by weight of raw opium). Other alkaloids present include codeine (1–3%), thebaine (1–2%), and papaverine (0.5–1%). Extraction involves dissolution in water, precipitation with lime, acid/base manipulations. See: Moffat AC, “Clarke’s Analysis of Drugs and Poisons,” Pharmaceutical Press.↩︎

60. Morphine is the principal alkaloid of opium (10–15% by weight of raw opium). Other alkaloids present include codeine (1–3%), thebaine (1–2%), and papaverine (0.5–1%). Extraction involves dissolution in water, precipitation with lime, acid/base manipulations. See: Moffat AC, “Clarke’s Analysis of Drugs and Poisons,” Pharmaceutical Press.↩︎

61. Morphine is the principal alkaloid of opium (10–15% by weight of raw opium). Other alkaloids present include codeine (1–3%), thebaine (1–2%), and papaverine (0.5–1%). Extraction involves dissolution in water, precipitation with lime, acid/base manipulations. See: Moffat AC, “Clarke’s Analysis of Drugs and Poisons,” Pharmaceutical Press.↩︎

62. Tasmania (Australia) produces approximately 50% of the world’s legal opiates, from Papaver somniferum varieties bred for high morphine or thebaine content. The Tasmanian industry operates under strict government licensing (Poppy Advisory and Control Board). See: Tasmania Department of Primary Industries, Parks, Water and Environment — Alkaloid Poppy Industry. The Indian and Turkish systems provide additional models for government-controlled opium production.↩︎

63. Chloroform was introduced as an anaesthetic by James Young Simpson in Edinburgh in 1847. It has a narrower therapeutic margin than ether and causes hepatotoxicity with repeated exposure. Historical mortality rate approximately 1:3,000 (vs. approximately 1:15,000 for ether). Chloroform must be stabilised with 0.5–1% ethanol to prevent phosgene formation during storage.↩︎

64. Chloroform was introduced as an anaesthetic by James Young Simpson in Edinburgh in 1847. It has a narrower therapeutic margin than ether and causes hepatotoxicity with repeated exposure. Historical mortality rate approximately 1:3,000 (vs. approximately 1:15,000 for ether). Chloroform must be stabilised with 0.5–1% ethanol to prevent phosgene formation during storage.↩︎

65. Chloroform was introduced as an anaesthetic by James Young Simpson in Edinburgh in 1847. It has a narrower therapeutic margin than ether and causes hepatotoxicity with repeated exposure. Historical mortality rate approximately 1:3,000 (vs. approximately 1:15,000 for ether). Chloroform must be stabilised with 0.5–1% ethanol to prevent phosgene formation during storage.↩︎

66. Chloroform was introduced as an anaesthetic by James Young Simpson in Edinburgh in 1847. It has a narrower therapeutic margin than ether and causes hepatotoxicity with repeated exposure. Historical mortality rate approximately 1:3,000 (vs. approximately 1:15,000 for ether). Chloroform must be stabilised with 0.5–1% ethanol to prevent phosgene formation during storage.↩︎

67. Penicillin G (benzylpenicillin) is produced by Penicillium chrysogenum fermentation. The discovery by Alexander Fleming (1928), development by Florey and Chain at Oxford (1939–1941), and scale-up in the US (1942–1945) constitute one of the most important stories in medical history. See: Lax E, “The Mould in Dr. Florey’s Coat,” Henry Holt, 2004.↩︎

68. Penicillin G (benzylpenicillin) is produced by Penicillium chrysogenum fermentation. The discovery by Alexander Fleming (1928), development by Florey and Chain at Oxford (1939–1941), and scale-up in the US (1942–1945) constitute one of the most important stories in medical history. See: Lax E, “The Mould in Dr. Florey’s Coat,” Henry Holt, 2004.↩︎

69. The first penicillin patient, Albert Alexander (a policeman with a facial wound infection), was treated in February 1941. He initially improved dramatically but died when the penicillin supply ran out — the Oxford team had produced only enough for five days of treatment. This illustrates the gap between demonstrating efficacy and achieving production scale.↩︎

70. Industrial penicillin fermentation: Penicillium chrysogenum NRRL 1951 and its mutagenised descendants are the standard production strains (yielding 40–50 g/L penicillin in modern industrial fermenters, compared to <0.1 g/L for Fleming’s original isolate). Fermentation conditions: 25–27°C, pH 6.5–7.5, aerated, 5–7 day batch. See: Elander RP, “Industrial production of β-lactam antibiotics,” Applied Microbiology and Biotechnology, 2003.↩︎

71. Industrial penicillin fermentation: Penicillium chrysogenum NRRL 1951 and its mutagenised descendants are the standard production strains (yielding 40–50 g/L penicillin in modern industrial fermenters, compared to <0.1 g/L for Fleming’s original isolate). Fermentation conditions: 25–27°C, pH 6.5–7.5, aerated, 5–7 day batch. See: Elander RP, “Industrial production of β-lactam antibiotics,” Applied Microbiology and Biotechnology, 2003.↩︎

72. Industrial penicillin fermentation: Penicillium chrysogenum NRRL 1951 and its mutagenised descendants are the standard production strains (yielding 40–50 g/L penicillin in modern industrial fermenters, compared to <0.1 g/L for Fleming’s original isolate). Fermentation conditions: 25–27°C, pH 6.5–7.5, aerated, 5–7 day batch. See: Elander RP, “Industrial production of β-lactam antibiotics,” Applied Microbiology and Biotechnology, 2003.↩︎

73. Industrial penicillin fermentation: Penicillium chrysogenum NRRL 1951 and its mutagenised descendants are the standard production strains (yielding 40–50 g/L penicillin in modern industrial fermenters, compared to <0.1 g/L for Fleming’s original isolate). Fermentation conditions: 25–27°C, pH 6.5–7.5, aerated, 5–7 day batch. See: Elander RP, “Industrial production of β-lactam antibiotics,” Applied Microbiology and Biotechnology, 2003.↩︎

74. Industrial penicillin fermentation: Penicillium chrysogenum NRRL 1951 and its mutagenised descendants are the standard production strains (yielding 40–50 g/L penicillin in modern industrial fermenters, compared to <0.1 g/L for Fleming’s original isolate). Fermentation conditions: 25–27°C, pH 6.5–7.5, aerated, 5–7 day batch. See: Elander RP, “Industrial production of β-lactam antibiotics,” Applied Microbiology and Biotechnology, 2003.↩︎

75. Industrial penicillin fermentation: Penicillium chrysogenum NRRL 1951 and its mutagenised descendants are the standard production strains (yielding 40–50 g/L penicillin in modern industrial fermenters, compared to <0.1 g/L for Fleming’s original isolate). Fermentation conditions: 25–27°C, pH 6.5–7.5, aerated, 5–7 day batch. See: Elander RP, “Industrial production of β-lactam antibiotics,” Applied Microbiology and Biotechnology, 2003.↩︎

76. Pharmaceutical quality control for injectable products: sterility testing (USP <71>), bacterial endotoxin testing (USP <85>), potency testing, purity testing (HPLC or titration), particulate matter testing. Each test requires specific reagents, equipment, and trained analysts. The quality control requirement is often more demanding than the production process itself.↩︎

77. Pharmaceutical quality control for injectable products: sterility testing (USP <71>), bacterial endotoxin testing (USP <85>), potency testing, purity testing (HPLC or titration), particulate matter testing. Each test requires specific reagents, equipment, and trained analysts. The quality control requirement is often more demanding than the production process itself.↩︎

78. Pharmaceutical quality control for injectable products: sterility testing (USP <71>), bacterial endotoxin testing (USP <85>), potency testing, purity testing (HPLC or titration), particulate matter testing. Each test requires specific reagents, equipment, and trained analysts. The quality control requirement is often more demanding than the production process itself.↩︎

79. Pharmaceutical quality control for injectable products: sterility testing (USP <71>), bacterial endotoxin testing (USP <85>), potency testing, purity testing (HPLC or titration), particulate matter testing. Each test requires specific reagents, equipment, and trained analysts. The quality control requirement is often more demanding than the production process itself.↩︎

80. Penicillin allergy: approximately 10% of patients report penicillin allergy, but true IgE-mediated allergy is confirmed in only approximately 1–2% on testing. Impure penicillin preparations (containing penicilloyl-protein conjugates) are more allergenic. See: Blumenthal KG et al., “Penicillin allergy,” New England Journal of Medicine, 2019.↩︎

81. Sulfonamides: the first class of synthetic antibiotics, discovered by Gerhard Domagk (1935, Nobel Prize 1939). Sulfanilamide is the simplest member. Synthesis from aniline via acetanilide, chlorosulfonation, amination, and deacetylation. See: Wainwright M, “The History of the Therapeutic Use of Crude Penicillin,” Medical History, 1987; and standard organic chemistry texts.↩︎

82. Sulfonamides: the first class of synthetic antibiotics, discovered by Gerhard Domagk (1935, Nobel Prize 1939). Sulfanilamide is the simplest member. Synthesis from aniline via acetanilide, chlorosulfonation, amination, and deacetylation. See: Wainwright M, “The History of the Therapeutic Use of Crude Penicillin,” Medical History, 1987; and standard organic chemistry texts.↩︎

83. Sulfonamides: the first class of synthetic antibiotics, discovered by Gerhard Domagk (1935, Nobel Prize 1939). Sulfanilamide is the simplest member. Synthesis from aniline via acetanilide, chlorosulfonation, amination, and deacetylation. See: Wainwright M, “The History of the Therapeutic Use of Crude Penicillin,” Medical History, 1987; and standard organic chemistry texts.↩︎

84. Procaine (Novocaine) was synthesised by Alfred Einhorn in 1905 as the first synthetic local anaesthetic safe for injection (cocaine, the earlier local anaesthetic, has addiction and toxicity problems). Procaine is an ester-type local anaesthetic with a shorter duration of action than lidocaine (amide-type) but is simpler to synthesise.↩︎

85. Catgut sutures: made from the submucosal layer of sheep or cattle intestine. Used in surgery for centuries. Chromic catgut (treated with chromium salts) absorbs more slowly (10–21 days vs. 5–10 days for plain catgut). Largely replaced by synthetic absorbable sutures (polyglycolic acid, polyglactin) in modern practice. See: Mackenzie D, “The History of Sutures,” Medical History, 1973.↩︎

86. Animal insulin extraction: first achieved by Frederick Banting and Charles Best (1921–1922, University of Toronto). The process involves: grinding fresh pancreas with acid-alcohol, filtering, precipitating insulin with acetone or ammonium sulfate, dissolving in acid, purifying by repeated precipitation, crystallising with zinc acetate. Historical yield: approximately 100–200 units per bovine pancreas. See: Bliss M, “The Discovery of Insulin,” University of Chicago Press, 1982.↩︎

87. Animal insulin extraction: first achieved by Frederick Banting and Charles Best (1921–1922, University of Toronto). The process involves: grinding fresh pancreas with acid-alcohol, filtering, precipitating insulin with acetone or ammonium sulfate, dissolving in acid, purifying by repeated precipitation, crystallising with zinc acetate. Historical yield: approximately 100–200 units per bovine pancreas. See: Bliss M, “The Discovery of Insulin,” University of Chicago Press, 1982.↩︎

88. Average insulin requirements for Type 1 diabetes: approximately 0.5–1.0 units/kg/day, or roughly 40–70 units/day for an average adult. Total NZ Type 1 insulin requirement: approximately 25,000 patients x 50 units/day average = 1.25 million units/day = approximately 450 million units/year.↩︎

89. Stats NZ / Beef + Lamb New Zealand. NZ has approximately 26 million sheep and 10 million cattle. Annual livestock processing provides raw materials including intestine (catgut), tallow (soap), lanolin (excipient), and pancreas (insulin extraction). Pig slaughter is approximately 600,000–700,000 per year.↩︎

90. Animal insulin extraction: first achieved by Frederick Banting and Charles Best (1921–1922, University of Toronto). The process involves: grinding fresh pancreas with acid-alcohol, filtering, precipitating insulin with acetone or ammonium sulfate, dissolving in acid, purifying by repeated precipitation, crystallising with zinc acetate. Historical yield: approximately 100–200 units per bovine pancreas. See: Bliss M, “The Discovery of Insulin,” University of Chicago Press, 1982.↩︎

91. Immunogenicity of animal insulin: bovine insulin differs from human insulin by 3 amino acids; porcine insulin by 1. Approximately 5–10% of patients on animal insulin historically developed anti-insulin antibodies, sometimes requiring species switching or desensitisation. Modern human insulin (recombinant) eliminated this problem — reverting to animal insulin reintroduces it. See: Fineberg SE et al., “Immunological responses to exogenous insulin,” Endocrine Reviews, 2007.↩︎

92. Paracetamol (acetaminophen) synthesis: p-aminophenol + acetic anhydride = paracetamol. The bottleneck is p-aminophenol, which requires nitrobenzene (from benzene + nitric acid) reduced to aniline, then oxidised and reduced again to p-aminophenol. Same coal tar/petrochemical dependency as aspirin and sulfonamides.↩︎

93. Modern antibiotic classes and their production: cephalosporins (semi-synthetic from Acremonium chrysogenum fermentation), macrolides (fermentation of Saccharopolyspora erythraea plus chemical modification), fluoroquinolones (total synthesis — 6–8 step synthesis from halogenated aromatic precursors), aminoglycosides (fermentation of Streptomyces species), carbapenems (semi-synthetic from Streptomyces cattleya fermentation). Each class requires industrial-scale fermentation or chemical synthesis beyond NZ’s near-term capability.↩︎

94. NZ AIDS Foundation / NZ Ministry of Health. Approximately 3,000–4,000 people are estimated to be living with HIV in NZ. Modern antiretroviral therapy (ART) requires combinations of drugs from multiple classes (NRTIs, NNRTIs, protease inhibitors, integrase inhibitors) — all complex synthetic molecules.↩︎

95. Cyclosporine: a cyclic peptide produced by Tolypocladium inflatum fermentation. Tacrolimus: a macrolide produced by Streptomyces tsukubaensis fermentation. Both require specialised fermentation and purification. See: Borel JF, “History of cyclosporin A and its significance,” in “Cyclosporin A,” Elsevier, 1986.↩︎

96. Ministry of Health NZ cancer statistics. Approximately 25,000 new cancer registrations per year in NZ. Cancer is the leading cause of death (~9,500 deaths per year). Without chemotherapy and targeted therapy, survival rates for many cancers decline substantially — though surgery alone is curative for some early-stage cancers.↩︎

97. Vaccine production: inactivated vaccines require growing live virus in cell culture (Vero cells, HEK-293 cells) and then chemically inactivating (formalin). Recombinant vaccines require genetic engineering and protein expression systems. mRNA vaccines require in vitro transcription and lipid nanoparticle formulation. All require specialised biotechnology infrastructure.↩︎

98. Measles herd immunity threshold: approximately 92–95% coverage required. See: Fine P et al., “Herd immunity: a rough guide,” Clinical Infectious Diseases 52(7):911–916, 2011. NZ annual birth registrations: approximately 58,000–62,000 per year (Stats NZ, 2023). Pre-vaccine measles case fatality in high-income countries: approximately 1–2 per 1,000 cases; in malnourished or low-income settings: 10–30%. See: WHO, “Measles fact sheet,” 2023; Griffin DE, “Measles virus-induced suppression of immune responses,” Immunological Reviews 236:176–189, 2010.↩︎

99. Measles herd immunity threshold: approximately 92–95% coverage required. See: Fine P et al., “Herd immunity: a rough guide,” Clinical Infectious Diseases 52(7):911–916, 2011. NZ annual birth registrations: approximately 58,000–62,000 per year (Stats NZ, 2023). Pre-vaccine measles case fatality in high-income countries: approximately 1–2 per 1,000 cases; in malnourished or low-income settings: 10–30%. See: WHO, “Measles fact sheet,” 2023; Griffin DE, “Measles virus-induced suppression of immune responses,” Immunological Reviews 236:176–189, 2010.↩︎

100. Ergometrine (ergonovine) is an ergot alkaloid used to control post-partum haemorrhage. It can theoretically be extracted from ergot (Claviceps purpurea), a fungus that infects rye and other cereals. However, ergot contains multiple toxic alkaloids (ergotamine, ergotoxine), and purifying ergometrine from the mixture is complex and hazardous. Misuse of crude ergot preparations causes ergotism (gangrene, convulsions). This is not a safe or simple production pathway.↩︎

101. Measles herd immunity threshold: approximately 92–95% coverage required. See: Fine P et al., “Herd immunity: a rough guide,” Clinical Infectious Diseases 52(7):911–916, 2011. NZ annual birth registrations: approximately 58,000–62,000 per year (Stats NZ, 2023). Pre-vaccine measles case fatality in high-income countries: approximately 1–2 per 1,000 cases; in malnourished or low-income settings: 10–30%. See: WHO, “Measles fact sheet,” 2023; Griffin DE, “Measles virus-induced suppression of immune responses,” Immunological Reviews 236:176–189, 2010.↩︎

102. Cardiovascular mortality impact of medication withdrawal is estimated from clinical trial data on the relative risk reduction provided by antihypertensives (~25–30% reduction in stroke, ~15–20% in coronary events) and statins (~25% reduction in major vascular events per 1 mmol/L LDL reduction). Withdrawal reverses these benefits. However, lifestyle changes (increased physical activity, weight loss, dietary changes) provide partial compensation. The net increase in cardiovascular mortality is uncertain. See: Law MR et al., BMJ 338:b1665, 2009; Cholesterol Treatment Trialists’ Collaboration, Lancet 376:1670, 2010.↩︎

103. NZ asthma prevalence and mortality: approximately 600,000 New Zealanders have asthma (Asthma and Respiratory Foundation NZ, 2021). NZ’s asthma mortality rate of 1.5–2.0 per 100,000 per year was among the highest in OECD nations during the 1990s–2000s, though has declined with improved management. See: Ministry of Health NZ, “Asthma,” updated 2022 (https://www.health.govt.nz/your-health/conditions-and-tre...); OECD Health Statistics 2023.↩︎

104. Pre-antibiotic surgical mortality: major surgery carried approximately 10–30% infection-related mortality before antibiotics, compared to <5% with modern antibiotic prophylaxis. See: Wainwright M, “Moulds in Folk Medicine,” Folklore, 1989; and historical surgical mortality data.↩︎

105. Stats NZ mortality data. NZ’s annual death rate is approximately 34,000–36,000 (crude death rate approximately 6.5–7 per 1,000 population).↩︎

106. Riley M, “Maori Healing and Herbal: NZ Ethnobotanical Sourcebook,” Viking Sevenseas NZ, 1994. Also: Brooker SG, Cambie RC, Cooper RC, “New Zealand Medicinal Plants,” Heinemann, 1981. These are the standard references for NZ medicinal plants, though both are dated and newer research exists for specific plants.↩︎

107. Mānuka honey: the antibacterial activity is primarily due to methylglyoxal (MGO), which is present at high concentrations in mānuka honey. Clinical evidence supports its use in wound care — it is approved as a medical device in multiple countries (Medihoney, Comvita Medical). See: Carter DA et al., “Therapeutic Manuka Honey: No Longer So Alternative,” Frontiers in Microbiology, 2016. NZ produces approximately 1,700–2,000 tonnes of mānuka honey per year.↩︎